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ABSTRACT 
 
 Recent research is aiming to elucidate the molecular mechanisms of metabolic 
syndrome-associated diseases. This study investigates iron overload-induced adiponectin 
resistance in cardiovascular disease and diabetes. Iron overloaded primary neonatal 
cardiomyocytes, L6 skeletal muscle myoblasts, and an in vivo mouse model was used to 
examine adiponectin resistance. Data indicates the induction of adiponectin resistance after iron 
treatment, and that this may occur by changes in adiponectin signalling proteins via the 
regulation of FOXO1 transcription factor. A decrease in adiponectin sensitivity was not observed 
in the iron overload mouse model used here, although this may be dependent on amount and 
duration of iron overload. Overall, this study sheds light on the complex balance of adiponectin 
signalling under iron overload conditions in heart and skeletal muscle. The data indicates that 
iron can induce adiponectin resistance, and thus helps to elucidate the cellular mechanisms via 
which metabolic syndrome disease complications can occur.   
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Chapter 1: Introduction and Research Aims 
1.1 Metabolic syndrome and associated complications 
 According to Metabolic Syndrome Canada, metabolic syndrome affects 1 in 5 
Canadians1, and accounts for 43% of deaths annually1. Metabolic syndrome is a combination of 
reversible physiological and molecular abnormalities that are positively correlated with the 
development of serious health conditions such as cardiovascular disease and  type 2 diabetes2. 
Symptoms such as abdominal weight gain, hypertension, as well as elevated triglyceride, 
glucose and cholesterol levels are all metabolic syndrome contributors. If diagnosed with 2 of 5 
of these conditions, a patient may be at high risk, while having 3 of 5 risks diagnoses a patient 
with metabolic syndrome3. Metabolic syndrome is treatable by making lifestyle changes such as 
maintaining a healthy weight, by exercising daily and by consuming a healthy diet2. However, 
lifestyle changes may not be the answer to all individuals. Thus, further investigations are 
required to better understand the molecular regulation of metabolic syndrome.  
1.1.1. Heart Failure 
 The metabolic syndrome characteristics mentioned previously are known to be 
associated with increased risk of heart failure4, whereby, cardiovascular disease is the number 
one cause of death worldwide5. A positive correlation between obesity and heart failure was first 
evident in the Framingham Heart study. This study investigated the relationship between Body 
Mass Index (BMI) and the prevalence of heart failure. An increased risk of heart failure in a 
given population was demonstrated via analysis of cardiovascular disease risk factors such as 
hypertension and blood suagr6.  
 The development of heart failure comprises both structural and functional abnormalities 
that impairs the heart from pumping sufficient blood supply to the body7. Heart failure is caused 
by a loss in functional myocardial cells after cardiac injury, which can result from etiologies such 
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as hypertension, ischemic heart disease and diabetes7. Moreover, heart failure results from a 
compensation for inadequate cardiac output. For instance, heart palpitations or an increased 
heart rate can result in insufficient blood flow in heart failure patients7. On the contrary, it has 
been reported that some cardiovascular disease risk factors are also known to play a 
cardioprotective role under certain circumstances - this is known as "reverse epidemiology". 
Specifically, high blood pressure and obesity have been shown to play beneficial roles in heart 
failure patients8,9. Overall, the relationship between these two risk factors is one that should be 
more thoroughly investigated.  
1.1.2. Diabetes 
 In 1922, Banting and Best discovered insulin; a hormone now known to regulate blood 
glucose levels10. When the body is unable to produce or respond to insulin, this results in a 
diseased state known as diabetes, whereby an abnormal metabolism of carbohydrates results 
in elevated blood sugar levels. Three types of diabetes include Type 1, type 2 and type 3 
diabetes. Type 1 diabetes, or juvenile onset diabetes, results from an autoimmune response 
against insulin producing islet cells in the pancreas. This results in elevated glucose levels in the 
blood stream, in turn leading to weight loss and increased risk of heart disease, stroke and 
kidney failure11. Type 2 diabetes, previously called adult onset diabetes, is caused by insulin 
resistance. Insulin resistance is the inability of cells to utilize normal insulin levels, which results 
in elevated plasma glucose11. This arises from reduced glucose uptake in muscle and other 
tissues, as well as beta cell failure. Furthermore, type 2 diabetes is also positively correlated 
with cardiovascular disease risk11. Lastly, recent research has now proposed a new category of 
diabetes, known as type 3 diabetes, or "brain diabetes". This type of diabetes is associated with 
elevated glucose levels in the brain, which may explain the shared molecular mechanisms with 
diabetes and elderly cognitive decline, more commonly known as Alzheimer's disease. 
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 Moreover, several studies have investigated the positive relationship between metabolic 
syndrome and type 2 diabetes risk12,13. For example, a study investigating the correlation 
between BMI and diabetes showed a strong relationship between a BMI over 40kg/m2 and self-
reported diabetes, as well as hypertension and elevated cholesterol14. Additionally, previous 
literature has also demonstrated a correlation between metabolic syndrome and type 2 diabetes 
via insulin resistance mechanisms15. However, further investigation is required to help 
understand the molecular regulation of metabolic syndrome associated diabetes. 
1.2 Obesity and adipokines 
 Recently, factors such as high fat diets and sedentary lifestyle have resulted in a global 
epidemic known as obesity16. Recently, obesity has become a rising topic in the fields of 
molecular biology and physiology because of its capability to increase the likelihood of various 
diseases that result in decreased life expectancy and morbidity17. Obesity is characterized by an 
accumulation of visceral fat tissue, and is marked by a BMI of 30kg/m² in Western society17. 
Visceral fat accumulation in obesity grows by two mechanisms. The first being hyperplasia, 
defined as elevated adipocyte number, which occurs at early stages of adipose tissue growth18. 
This is then followed by hypertrophy, defined by an increase in cell size, which occurs due to 
lipid storage overload, resulting in lipid redistribution into other metabolic tissues19. Hypertrophic 
adipose tissues also have an altered adipokine secretion profiles. Adipokines are adipose 
tissue-specific cytokines (cell signalling proteins). For example, leptin was the first discovered 
adipokine in 1994. Leptin is a 16 kilodalton (kDa) protein, also known as the satiety hormone, is 
involved in decreasing food intake and increasing energy consumption in healthy individuals. It 
is found to be inversely correlated with increasing amounts of adipose tissue20. Conversely, 
lipocalin-2 is an adipokine found to be positively correlated with body fat percentage, and is 
involved in apoptosis (cell death) regulation and iron metabolism. Lastly, adiponectin is an 
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adipokine known to play multiple beneficial roles in cellular homeostasis, and will be the focus of 
this introduction. 
1.2.1. Adiponectin structure  
 Adiponectin, also known as AdipoQ, Acrp30 and apM1, is a 30kDa protein that is found 
in abundantly high levels in circulation and is found at concentrations of ~1-30µg/ml21,22. 
Adiponectin is comprised of a 247 amino acid sequence and consists of three domains: an 
amino-terminal signal sequence, a collagenous domain, and a carboxyl-terminal globular 
domain at the C-terminal end22,23. The adiponectin monomer is found in two forms in circulation: 
full length adiponectin (fAd) and globular adiponectin (gAd). Full length adiponectin (fAd) is 
found in three oligomeric forms: high molecular weight (HMW), middle molecular weight (MMW) 
and low molecular weight (LMW)24, found in oligomer, hexamer and trimer chains, respectively. 
Specifically, three monomers attach through interactions via their globular domains (LMW), two 
trimers use the collegoneous domain to form a hexamer (MMW), and 4-6 trimers will form an 
oligomer in the same manner (HMW)25. The oligomerization states of adiponectin have been 
previously shown to be important for biological functioning26. Moreover, fAd can become 
cleaved by leukocyte elastase to release the C-terminal fragment and create what is known as 
globular adiponectin (gAd)27. 
1.2.2. Adiponectin in metabolic syndrome 
 Adiponectin plays many beneficial roles against metabolic syndrome associated 
diseases through its anti-inflammatory, anti-apoptotic, anti-diabetic and cardioprotective 
properties17. Moreover, adiponectin has been shown to be inversely proportional to body fat 
percentage in adults28,29. For instance, a study in 1996 showed reduced adiponectin levels in 
obese (ob/ob) mice30, and a 1999 study showed decreased plasma adiponectin levels in obese 
patients31. Moreover, studies have revealed that this decrease in adiponectin is explained by 
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both environmental and genetic factors. For instance, a reduction in adiponectin can be caused 
by any point mutation in the adiponectin gene32. Furthermore, a decrease in adiponectin can 
also occur as a result of unhealthy lifestyle choices such as a high-fat diet and lack of exercise. 
This is supported by previous studies which have shown that a healthy diet and combined with 
exercise significantly increased adiponectin levels via insulin signalling regultion33,34. Overall, 
this decrease in adiponectin in obese individuals has the potential to lead to metabolic diseases. 
The following information will focus on adiponectin in cardiovascular and diabetes. 
1.2.2.1. Adiponectin and cardiovascular disease  
 Previous research has demonstrated a cardioprotective role of adiponectin against 
cardiovascular disease, as well as its potential as a therapeutic target35. For instance, studies in 
adiponectin knockout (KO) mice showed increased cardiac hypertrophy and mortality, 
suggesting a cardioprotective role by adiponectin36,37. Another study showed that adiponectin is 
protective against severe cardiac fibrosis38. Additionally, clinical investigations have confirmed a 
rapid decline in adiponectin levels following acute myocardial infarction (MI)39.  Moreover, 
significant reduction in adiponectin levels were observed under oxidative stress conditions in 
cultured cardiomyocytes. Reactive oxygen species (ROS) and oxidative cell death were 
significantly decreased with adiponectin treatment40. Despite these findings, the relationship 
between adiponectin levels and heart failure is somewhat controversial. For instance, a clinical 
study showed high adiponectin levels are positively correlated with mortality in heart failure 
patients41; however, the mechanistic regulation of this finding is currently poorly defined. In 
conclusion, further investigation is required to better understand the role of adiponectin 
regulation in cardiovascular disease.  
1.2.2.2. Adiponectin and diabetes  
 Adiponectin has also been a recent therapeutic target for diabetes treatment due to its 
anti-diabetic properties42. Previous research suggests the development of diabetes in 
6 
 
adiponectin depleted conditions. Results show that lack of adiponectin leads to reduced glucose 
and fatty acid uptake, as well as increased gluconeogenesis21,43. A clinical study in Japan also 
confirmed higher circulating adiponectin levels are correlated with a decreased risk of type 2 
diabetes in adults44. Moreover, the negative relationship between adiponectin and insulin 
resistance has been well characterized in literature45,46,47. Overall, these findings suggest a 
strong relationship between decreased adiponectin and diabetes risk. Recent literature has 
suggested the potential regulation of adiponectin mediated insulin resistance via inflammasome 
activation. Specifically, up-regulation of tumour necrosis factor α (TNF-α) and interleukin-6 (IL-6) 
have been shown to attenuate insulin sensitivity48,49. However, further investigation is needed to 
fully elucidate the molecular mechanisms of adiponectin regulation in diabetes.  
1.2.3. Adiponectin signalling and action 
 Adiponectin action occurs via two receptors: adiponectin receptor 1 (AdipoR1/AdR1) and 
adiponectin receptor 2 (AdipoR2/AdR2)20. AdipoR1 is predominantly found in skeletal muscle, 
while AdipoR2 is abundant in the liver. In addition to AdipoR1 and AdipoR2, T-cadherin (T-cad) 
is a non-transmembrane adiponectin receptor. T-cad specifically binds to HMW and MMW 
adiponectin in circulation, and T-cad knockout (KO) mice have been shown to cause increased 
adiponectin concentrations in circulation50,51. Although T-cadherin is important for adiponectin 
binding in serum, it is thought that it plays no critical role in adiponectin signalling due to its lack 
of a transmembrane domain51. 
 AdipoR1 and AdipoR2 are transmembrane proteins, each with 7 transmembrane 
domains (Figure 1.1). Moreover, AdipoR1 and AdipoR2 have an external C-terminus and an 
internal N- terminus52.  AdipoR1 and AdipoR2 are known to bind to certain adaptor proteins 
such as leucine zipper motif 1 (APPL1)53. APPL1 has a phosphotyrosine binding domain that 
binds to the N-terminus of AdipoR1, which stimulates phosphorylation of AMPK (adenosine 
monophosphate-activated protein kinase) and P38 MAPK (mitogen-activated protein kinases)54. 
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 AMPK is a serine/threonine protein kinase that is comprised of 3 subunits: α, β and γ. 
The catalytic α subunit is activated at threonine (Thr) 172, while β and γ are regulatory subunits. 
Specifically, an increase in adenosine mono-phosphate (AMP) causes γ subunit binding, 
leading to AMPK activation via Thr172 phosphorylation. This effect is reversed by elevated 
adenosine tri-phosphate (ATP) levels55.  AMPK regulation is also mediated by two upstream 
kinases: liver kinase B1 (LKB1) and Ca2+/calmodulin-dependent protein kinase kinase 
(CaMKK); both of which are serine and threonine kinases that increase AMPK activity. 
Specially, adiponectin promotes LKB1 translocation from the nucleus to the cytosol, which is 
also assisted by APPL1 via BAR (membrane binding) domain interaction56. In terms of CaMKK, 
adiponectin stimulates endoplasmic reticulum (ER) mediated calcium release via phospholipase 
C activation, causing AMPK activation which is LKB1 independent56. P38 is also a 
serine/threonine kinase that is regulated by adiponectin in an APPL1 dependant manner. 
APPL1 acts as a scaffolding protein for P38 activation via Transforming growth factor β 
activated kinase (TAK1)-mitogen-activated protein kinase kinase 3  (MKK3)57. 
 APPL2, an APPL1 isoform, also binds to AdipoR1 and AdipoR2. Unlike APPL1, APPL2 
negatively regulates AdipoR1 and AdipoR2 dependant signalling. Additionally, APPL2 binds 
with APPL1 to form a complex via BAR domain interactions. This interaction between APPL1 
and APPL2 causes APPL1 to compete for adiponectin receptor binding. Furthermore, 
adiponectin disrupts APPL2 receptor binding, in order to allow for an APPL1 dependant 
signalling cascade58. 
 AdipoR1 and AdipoR2 display preferences for certain downstream signalling molecules. 
AdipoR1 prefers to stimulate AMPK while AdipoR2 is more is involved in PPARα (peroxisome 
proliferator-activated receptors) activation53. PPARs are nuclear receptor proteins that are 
involved in changing gene expression following a signalling cascade. Specifically, PPARα and 
PPARγ are known to regulate transcription factors that monitor glucose and lipid metabolism59. 
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Figure 1.1: A summary of adiponectin signalling. Adiponectin has two transmembrane 
receptors: AdipoR1 and AdipoR2. Receptor activation upon adiponectin to receptor binding 
leads to the binding of APPL1 adaptor protein, which is competitively regulated by APPL2. 
APPL1 to receptor binding initiates activation of adiponectin mediated P38 and AMPK 
stimulation via phosphorylation, and subsequently glucose uptake.  
 
1.2.3.1. Adiponectin stimulated metabolism 
 Adiponectin is involved in modulating a number of metabolic processes such as glucose 
uptake and fatty acid oxidation16. Fatty acid metabolism is regulated through phosphorylation of 
acetyl-coenzyme A (CoA) carboxylate (ACC), while glucose uptake is regulated by glucose 
transporters types 1-4 (GLUT1-4). GLUT1 is mainly prevalent on the surface of the neonatal 
heart. GLUT2 is predominately abundant in the kidney, pancreas, liver and small intestine. 
GLUT3 is highly expressed in the brain, but has also been shown to be expressed in skeletal 
muscle and the heart in low levels. GLUT4 is highly expressed in tissues that are insulin 
sensitive such as adipose tissue and the adult heart, but it is mainly expressed in skeletal 
muscle60.  
 Adiponectin has been shown to stimulate both metabolic fatty acid uptake and glucose 
uptake in the heart. Adiponectin stimulates glucose uptake via GLUT4 translocation to the 
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plasma membrane53. GLUT4 translocation can occur via the activation of AMPK, P38, and Ras-
related protein 5 (Rab5); all of which are activated through APPL1 dependant adiponectin 
receptor activation61. Additionally, adiponectin is known to enhance insulin stimulated glucose 
uptake via Akt (protein kinase B) phosphorylation62. Focusing on fatty acid oxidation, 
adiponectin is known to stimulate lipoprotein lipase (LPL) translocation to the plasma membrane 
which causes the break-down of low density lipoproteins in circulation63.  In turn, cardiac 
metabolic regulation is essential and crucial as the accumulation of sugar or fatty acid chains in 
the heart can lead to cardiac dysfunction60. 
  Adiponectin is also known to regulate glucose and fatty acid metabolism in skeletal 
muscle. AMPK activation is known to regulate adiponectin induced metabolic pathways64. 
Additionally, other research has demonstrated P38 is also involved in glucose uptake regulation. 
Activation of P38 and AMPK by adiponectin then results in GLUT4 translocation to the plasma 
membrane, causing receptor internalization via endocytosis61. In terms of fatty acid metabolism, 
the activation the AMPK pathway upon adiponectin stimulation is known to stimulate ACC 
phosphorylation. This causes a downstream inhibitory effect of ACC, which results in a 
reduction in malonyl-CoA, therefore increasing fatty acid-oxidation. Moreover, a study in C2C12 
skeletal muscle cells revealed that adiponectin induces fatty acid oxidation via AMPK, P38 and 
PPARα, which also cause LPL membrane translocation59.  
1.2.3.1 Adiponectin receptor regulation by FOXO 
 Adiponectin receptor expression is regulated by the action of specific transcription 
factors, including Forehead box protein (FOXO). The FOXO transcription factors are involved  in 
a number of cellular processes such as cell cycle control, cell differentiation, stress response 
and apoptosis65. The FOXO family consists of four subgroups: FOXO1, FOXO3, FOXO4 and 
FOXO6. Each subgroup is known for its tissue-specific expression. FOXO4 is expressed in 
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muscle and kidney, while FOXO6 is expressed in the liver and primarily the brain. FOXO1 and 
FOXO3 are abundantly expressed in all tissues66. 
 FOXO regulation is dependent on post translational modifications including 
phosphorylation, acetylation, methylation and ubiquitination. In terms of phosphorylation, the 
phosphoinositide 3 kinase (PI3K) pathway is known to inhibit FOXO regulation via serum 
glucocorticoid inducible kinase (SGK) and Akt. For instance, phosphorylation of FOXO1 by SGK 
or Akt at residues Thr24, Ser256 and Ser319 result in a change in cellular localization from  the 
nucleus to the cytoplasm, whereby FOXO1 becomes transcriptionally inactive67. For example, 
gene expression of AdipoR1 and AdipoR2 is controlled by nuclear FOXO168.  Moreover, FOXO 
can be activated by acetylation via macrophage stimulating protein 1 (MST1), c-Jun N-terminal 
kinases (JNK) and Cyclin-dependent kinase 1 (CDK1). This results in a change FOXO 
localization from the cytoplasm to the nucleus where it becomes transcriptionally active65. 
Conversely, acetylation of FOXO has been shown to inhibit its DNA binding capacity69. The 
acetylated state of FOXO is regulated by histone deacyteltransferases (HDACs) and histone 
acyteltransferases (HATs). HDACs such as Silent Information Regulator 2 (SIRT1/2) and HATs 
such as CREB Binding Protein (CBP/p300), regulate FOXO by promoting or deactivating 
transcription, respectively70,69. In terms of ubiquitination, FOXO can be either mono- or 
polyubiquitinated71,72. Monoubiquitination of FOXO leads to activation of its transcriptional 
activity in the nucleus, while polyubiquitination results in FOXO localization to the cytoplasm, 
followed by its degradation. Deubiquitination can also reactivate FOXO under certain 
conditions71. Lastly, there are certain kinases that can regulate transcriptional activity of FOXO. 
For instance, AMPK dictates the transcriptional profile of FOXO by recruiting other proteins to 
regulate FOXO transcription73.   
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1.2.3.2. AdipoRon, an adiponectin agonist 
 Adiponectin has been considered a therapeutic target for metabolic syndrome 
associated disease due to the observation that adiponectin levels are reduced in obese 
individuals. However, adiponectin as a therapeutic agent is not readily available due to its 
expensive production74. Moreover, adiponectin cannot be orally administered due to proteolysis 
of the hormone, affecting its ability to reach the bloodstream75. Currently, there are two 
adiponectin agonists, ADP 355 and AdipoRon (AdRon) which are under investigation. A recent 
cancer study investigated the effects of ADP 355, a peptide-based adiponectin receptor agonist, 
via intraperitoneal (IP) administration. It was discovered that ADP 355 has the ability to repress 
breast cancer tumour growth via adiponectin receptor stimulation35. In addition to ADP 355, 
AdRon is also another adiponectin agonist that acts via AMPK signalling pathways, and will be 
the focus of this introduction.  
 AdRon, discovered by Okada-Iwabu et al76, is the first orally active adiponectin receptor 
stimulator77. AdRon binds to both AdipoR1 and AdipoR2, which then stimulates adiponectin 
action signalling pathways via AMPK and PPARα, respectively. AdRon was also shown to 
improve cardiac function after reperfusion injury by preventing cardiomyocyte apoptosis after 
MI77. Orally administered AdRon was shown to reduce fasting plasma glucose and insulin levels 
in HF diet mice. This effect was diminished in AdipoR1 and AdipoR2 double KO mice. AdRon 
has also been shown to reduce plasma glucose levels, triglyceride content, oxidative stress and 
inflammation in diabetic phenotype (db/db) mice, while also increasing lifespan76. Overall, 
AdRon is a promising therapeutic approach to treat cardiovascular disease and type 2 diabetes. 
However, further investigations are required to better understand the mechanism of AdRon 
action in metabolic syndrome associated disease.  
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1.3 Adiponectin resistance  
 It is known that adiponectin levels are inversely proportional to body fat percentage in 
adults78.  As a result, decreased adiponectin levels also reduce adiponectin action in these 
individuals. However, it remains unclear if lack of adiponectin action is due to a subnormal 
biological response to normal, or lower than normal, amounts of adiponectin. This phenomenon 
is known as adiponectin resistance. Adiponectin resistance is currently a rising topic in the fields 
of molecular biology; however, the physiological significance and mechanisms remain poorly 
defined79.  
 Adiponectin resistance has been linked to heart failure and diabetes80,81,82. For example, 
an investigation in H9c2 cardiomyocytes examined the role of lipotoxicity induced ER stress and 
autophagy. A decrease in adiponectin sensitivity was observed via reduced AMPK signalling as 
well as reduced APPL1 mRNA and protein expression. These findings suggest that adiponectin 
resistance occurs in a model of lipotoxicity induced heart failure83. Multiple studies have also 
indicated adiponectin resistance in chronic heart failure79,84. Metabolic failure has been 
previously linked to heart failure pathophysiology, by a reduction in AdipoR1, AMPK and PPARα 
expression84. Moreover, adiponectin resistance is seen in heart failure patients with altered 
glucose and lipid metabolism. Importantly, a reduction in AdipoR1 has provided great insight for 
adiponectin resistance regulation mechanisms79. Moreover, a study conducted in insulin 
resistant obese mice (ob/ob), showed a reduction in AdipoR1 protein expression in skeletal 
muscle 68. Another study examined the effects of gAd on a HF diet mouse model. It was 
demonstrated that gAd did not induce fatty acid oxidation in HF diet mice, suggesting gAd 
resistance85. Overall, these findings suggest that further investigation is needed in order to 
better understand the mechanism of adiponectin resistance regulation in cardiovascular 
diseases and diabetes.  
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1.4 Iron and iron transport 
 Iron is an essential mineral necessary for multiple bodily functions. Specifically, iron is a 
main component of hemoglobin; a protein composed of four subunits, each containing an iron 
bound atom to form a "Heme" group. Moreover, iron is naturally present in many foods, and is 
found in two forms: heme and non-heme. Sources of non-heme iron include plant sources and 
fortified foods, while heme and non-heme iron are present in animal products such as red meats 
and poultry86. Iron supplements can also provide daily iron doses, and is often found in either 
ferrous (Fe2+) or ferric forms (Fe3+), both of which are absorbed equally well87. The type of iron 
depends on the site in the body during its absorption. Non-heme dietary iron enters the gut via 
duodenal enterocytes88,89. Before entering the cell, ferric iron is reduced into ferrous iron by 
reducatase duodenal cytochrome b (Dcytb), and enters through a divalent metal-ion transporter 
(DMT1). Heme iron enters the cell by endocytosis. It is thought that heme transport across the 
enterocyte plasma membrane is assisted by haem carrier protein 1 (HCP1), which is then 
released by haem oxygenase (HO1)89. Iron in the cytoplasm is then stored in a protein-iron 
complex called ferritin, as free iron is toxic to cells. Iron can also be released from ferritin upon 
its  lysosomal degradation90. Free iron then exits the cell using iron exporter ferroportin, a 
multipass transmembrane protein91. Additionally, ferroportin levels are regulated by iron-
regulatory hormone, hepcidin. Hepcidin and ferroportin levels are inversely proportional. Low 
hepcidin and increased ferroportin levels cause increased iron efflux, leading to an iron overload 
state. Lastly, upon iron release into circulation through ferroportin, iron is bound in the 
bloodstream by the transport glycoprotein named transferrin92.  
1.4.2. Iron overload  
 Iron uptake is a process that is tightly regulated in the body, as there are no 
physiological processes that prioritize iron excretion89. The dysregulation of iron can lead to an 
iron overload state, which can cause iron overload disorders. Clinically known as 
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haemochromatosis, iron overload disorders result from three different circumstances: genetic 
mutations, through multiple blood transfusions and by dietary iron supplement overload. Most 
commonly, hereditary hemochromatosis is due to mutations in the hepcidin gene, formally 
known as hepcidin antimicrobial peptide (HAMP)93. Mutations that are also known to cause 
hereditary hemochromatosis are found in other iron regulatory proteins such as HFE (also 
known as the hemochromatosis protein), transferrin receptor 2 (TFR2) or hemojuvelin (HFE2, or 
HJV)94,95,96. These mutations impair or reduce iron detection by hepatocytes, which in turn 
reduces hepcidin transcription93. Consequently, these decreased hepcidin levels lead to 
reduced ferroportin regulation, resulting in iron overload in multiple tissues. Hemochromatosis 
can also be caused by transfusion-induced iron overload in anemic patients. Anemia, is a 
condition marked by a deficiency in red blood cell production, which is accompanied by a 
reduction in circulating and cellular iron levels. Severe anemia is treated via blood transfusions, 
whereby donated blood is transfused into the patient via intravenous (IV). Although blood 
transfusions are a temporary treatment for anemic patients, multiple blood transfusions can lead 
to iron overload. Transfused red blood cells undergo a process called erythrophagocytosis, 
whereby red blood cells are ingested by macrophages or other immune cells97. This excess iron 
manages to surpass transferrin, ultimately leading to excess free iron in the targets tissues. As a 
result, cumulative iron overload  leads to toxicity, causing organ dysfunction and damage97,98. 
Lastly, iron overload can also be caused by the consumption of excess iron supplements. A 
clinical study in 2006 concluded that only patients with documented iron deficiencies should be 
taking iron suppliments99. Moreover, it is important that physicians should carefully supervise 
iron supplement therapy. Regardless of the cause, iron overload has been shown to cause 
organ damage and other harmful effects. Specifically, haemochromatosis causes symptoms 
such as skin darkening, fatigue, weakness, joint pain and stomach pain. However, on a larger 
spectrum, iron overload has also been shown to cause reproductive problems, liver disease, 
cancer, cirrhosis, heart disease, and diabetes. 
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1.4.2.1. Iron overload and heart disease  
 Iron overload has been linked to cardiomyopathy100, due to the ability of iron to increase 
cardiac oxidative stress and fibrosis101. However, clinical methodologies to diagnose iron 
overload induced heart disease are still unknown. In addition, iron overload induced heart 
disease has been shown to be is potentially lethal and thus, further study is required to improve 
clinical diagnosis. For instance, newer insight on iron-specific imaging techniques are being 
developed for iron overload induced cardiac disease to detect cardiomyopathy at earlier 
stages100. Additionally, the role of iron chelators and genetic therapies are in progress, but still 
require further mechanistic investigation. Overall, iron overload associated cardiomyopathy still 
requires further exploration in metabolic syndrome associated cardiac disease.  
1.4.2.2. Iron overload and diabetes  
 The link between iron overload and diabetes has been recently well identified102. Iron is 
known to play a role in regulating glucose metabolism103, as well as insulin resistance 
regulation104. Specifically, in hemochromatosis patients, iron is known to accumulate in the 
pancreas, where it may have a negative effect on beta cell function via increasing oxidative 
stress and apoptosis. This in turn affects insulin secreting mechanisms and glucose 
metabolism. This was demonstrated by a group who investigated hereditary hemochromatosis 
mouse models. It was found that iron overload mice displayed a loss in the capacity to secrete 
insulin105. An additional study demonstrated that iron overload has been shown to accumulate in 
adipoctyes. This investigation showed that increased iron was also associated with increased 
ferritin levels, which has been previously shown to be positively correlated with diabetes risk via 
insulin resistance106. Moreover, mice fed with a high iron diet were shown to have a decreased 
level of serum adiponectin compared to mice fed with normal chow. To conclude these findings, 
the overall mechanistic regulation of iron overload induced disease requires further study. 
Furthermore, the underlying molecular mechanisms of iron overload induced disease via 
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adipokine regulation, such as adiponectin, currently remains misunderstood and also requires 
further investigation102.  
1.5 Hypothesis and aims 
 Adiponectin is known for its anti-diabetic, anti-inflammatory, anti-fibrotic and 
cardioprotective properties. Therefore, patients with metabolic associated diseases display a 
lower profile of the beneficial effects mediated by adiponectin. However, it is unclear whether a 
lack of adiponectin action in patients with metabolic syndrome associated disease is due to a 
resistance in already reduced adiponectin levels in circulation. Thus, the aim of my thesis is to 
prove the presence of adiponectin resistance, as well as define the underlying molecular 
mechanisms. Specifically, I am interested in iron overload induced adiponectin resistance in 
both heart disease and diabetes, as this a phenomenon that is not well characterized in the 
literature.  
 Therefore, my first hypothesis is that adiponectin resistance will be induced under iron 
overload conditions. This phenomenon will be studied by examining iron overloads effects on 
the gene expression of downstream adiponectin signalling molecules, as well as through 
changes in adiponectin sensitivity under iron overload conditions. Previous studies have defined 
adiponectin resistance via reduced expression levels of adiponectin receptors (AdipoR1 and 
AdipoR2)  and their corresponding adaptor protein (APPL1) 68,79, which results in a lack of 
adiponectin action.  
 The mechanism of iron overload induced adiponectin resistance is further hypothesized 
to be regulated by FOXO1 - an AdipoR1 and AdipoR2 transcription factor. I am proposing that 
iron overload conditions stimulate FOXO1 cytoplasmic localization to the cytoplasm, affecting its 
ability to transcribe AdipoR1 and AdipoR2. This could explain the lack of adiponectin action in 
iron overload conditions. The role of FOXO1 in iron overload induced adiponectin resistance will 
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be examined by tracking FOXO1 localization under iron overload conditions through anti-
FOXO1 immunofluorescence. Moreover, the use of a FOXO1 inhibitor will be used to 
understand the functional significance of FOXO1 under iron overload conditions. Specifically, 
upon co-treatment of iron overload with a FOXO1 inhibitor in cell culture, the reversal of reduced 
adiponectin expression could confirm FOXO1`s role in iron overload induced adiponectin 
resistance regulation.  
 The following research aims will be investigated via three different models to examine 
heart disease and diabetic conditions: in vitro L6 skeletal muscle cells, ex vivo primary rat 
neonatal cardiomyocytes and an in vivo iron overload mouse model. Thus, I propose the 
following investigations of iron overload induced adiponectin resistance: 
Study1: The investigation of iron overload induced adiponectin resistance in the heart, 
featuring ex vivo neonatal cardiomyocytes and an in vivo iron overload mouse model.  
Study 2: The investigation of iron overload induced adiponectin resistance in skeletal 
muscle, featuring in vitro L6 skeletal muscle cells an in vivo iron overload mouse model. 
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Chapter 2: The investigation of iron overload induced adiponectin 
resistance in the heart, featuring ex vivo neonatal cardiomyocytes 
and an in vivo iron overload mouse model 
2.1 Preface 
 The relationship between metabolic syndrome and heart disease is one that has been 
recently investigated in the literature. Iron overload has been linked to both metabolic syndrome 
and heart disease; however the involvement of adipokines, such as adiponectin, in the 
molecular regulation of iron overload associated heart disease is not well characterized. 
Furthermore, whether iron overload induces adiponectin resistance is not yet established. In 
addition, iron overload induced regulation by FOXO1 transcription factor has not been well 
characterized. Ex vivo primary neonatal cardiomyocytes treated with iron and an in vivo iron 
overload mouse model were used to examine the molecular regulation of iron overload induced 
adiponectin resistance. Decreased AdRon stimulated pAMPK, pP38 and glucose uptake were 
observed in iron overload conditions, and reduced AdipoR1 and APPL1 expression levels 
provide a potential mechanistic foundation for adiponectin resistance. Moreover, alleviatory 
affects of iron overload induced adiponectin resistance were relieved by inhibiting FOXO1, 
suggesting its mechanistic involvement in adiponectin resistance regulation. Conversely, 
adiponectin resistance was not evident in the heart of iron overload mice, suggesting the 
complex balance of adiponectin signalling under stress. Moreover, using echocardiography, 
impaired cardiac function was observed in iron overload compared to control mice. In summary, 
FOXO1-regulated iron overload induced adiponectin resistance was shown in neonatal 
cardiomyocytes. Together, these results suggest altered adiponectin regulation in iron overload 
conditions, supporting the potential mechanisms for iron overload induced cardiac disease and 
potential drug targeting.  
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2.2 Introduction 
 A cluster of health conditions associated with metabolic syndrome is known to be 
positively correlated with the prevalence of cardiovascular disease2 - the leading cause of death 
worldwide5. Cardiovascular disease is characterized by both structural and functional 
abnormalities that impair cardiac function, which results from conditions such as hypertension 
and ischemia7. The molecular regulation of metabolic syndrome induced heart disease has 
been strongly linked to adipokine-mediated signalling. Specifically, the link between adiponectin 
and heart failure has been extensively investigated in previous research107,83,85. Adiponectin 
plays  beneficial roles against metabolic related diseases by being cardioprotective against 
heart failure17, 108,109,110. However, adiponectin has also been inversely related to late stage heart 
disease78. Therefore, it remains unclear if lack of adiponectin action in heart failure is due to a 
subnormal biological response to normal, or lower than normal, amounts of adiponectin. This 
phenomenon known as adiponectin resistance is a rising topic in the field. However, the 
physiological significance and mechanisms of this particular adiponectin regulation remains 
unclear79. 
 Emerging studies suggest a correlative, yet poorly characterized relationship between 
cardiovascular disease and iron overload100. The link between iron overload induced 
adiponectin resistance in the heart is also a phenomenon that remains poorly defined. 
Therefore, this chapter aims to examine iron overload induced adiponectin resistance. This topic 
will be studied by examining changes in adiponectin sensitivity as well as through changes in 
adiponectin signalling protein expression. Upon the presence of iron overload induced 
adiponectin resistance, it is further hypothesized that FOXO1 - a transcription factor regulating 
AdipoR1 and AdipoR2 68 - will control iron overload induced adiponectin resistance in the heart. 
These hypotheses will be examined in ex vivo primary rat neonatal cardiomyocytes and in the 
heart of an in vivo mouse model.  
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2.3 Materials and Methods 
2.3.1 Neonatal Cardiomyocyte Isolation and Culturing 
 The left ventricles of 1-3 day Wistar rat (Rattus Norvegicus) pups were isolated by 
decapitation, followed by a small ventricle incision through the sternum. Hearts were rinsed with 
CFBHH (Calcium and Bicarconate Free Hanks with Hepes) buffer (NaCl [137mM], [KCl 
5.36mM], MgSO4 [0.81mM], Dextrose [5.55], KH2PO4 [0.44], Na2HPO4 [0.34], HEPES pH 7.4 
[20.06]) and torn apart into small pieces with fine tweezers. Samples were transferred to a flat 
bottom 50ml conical tube with 10ml of trypsin (1:250) (Gibco #27250-018) dissolved in CFBHH 
buffer and a small stir bar. Heart pieces were stirred in the cell culture hood on a magnetic plate 
for 10 min. The supernatant was collected and neutralized with DMEM (Gibco DMEM F12 with 
L-Glutamine and 2.438 g/L sodium bicarbonate #11320) supplemented with 10% Fetal Bovine 
Serum (FBS) (Wisent Inc #080-150), 1% Penicillin-Streptomycin (Gibco #15070063) solution 
and 50mg/L Cellgro  Gentamycin sulfate (Life Technologies#30-005-CR). 10ml of trypsin was 
added to the remaining sample, and these series of steps were repeated until all tissue was 
digested into a homogenous solution. Homogenized tissue was spun down at 2000RPM for 
20min, supernatant was removed, and pellet was respuspened in 10%FBS DMEM. Cells were 
plated in 10cm2 culture dishes (Falcon #6220065) for 1 hour in order to separate fibroblasts from 
cardiomyocytes. After incubation in a CO2 incubator at 37ºC, supernatant containing 
cardiomyocytes was filtered through a 70µm nylon strainer (BD Falcon Cell Strainer 70µm 
Nylon #352350).  Filtrate was supplemented with additional 10% FBS DMEM, and plated on 
primaria coated culture dishes (Falcon multiwell primaria 6 well #35-3846, 24 well #35-3847, 96 
well#35-3848). 24 hours after isolation, cells were washed with Phosphate Buffer Saline (PBS) 
(Wisent 1X PBS, #311-010-CL). Treatment media (0%, 0.5% or 2% FBS DMEM) was added to 
begin experiments.  
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2.3.2. Characterizing intracellular iron: 
2.3.2.1. MTT Assay 
 Neonatal cardiomyocytes were plated onto a primaria coated 96 well plate, and treated 
at  0µm, 100µm and 250µm of FeCl3 (Sigma #44944) dissolved in dH2O. Iron overload treatment 
was incubated for 24 hours (24h) in 0.5% FBS DMEM media. 5mg/ml of 
Methylthiazolyldiphenyl-tetrazolium (MTT,3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide) (Sigma #M5655-1G) dissolved in PBS was added to each well 5 hours 
before the end of 24h treatment. Treatment media was removed with a needle syringe. 
Maximum working well volume (200µl per well in a 96 well plate) of dimethyl sulfoxide (DMSO) 
(Biopshop #DMS 555.500) was added to each well and incubated in a CO2 incubator at 37ºC for 
5 minutes. Absorbance was measured at 550nm. 
2.3.2.2 IRE-CFP 
 Iron Response Element - Cyan Fluorescent Protein (IRE-CFP) plasmid was kindly 
provided by Dr. James R. Connor at Penn State Hershey Medical Centre. Transfection of IRE-
CFP into neonatal cardiomyocytes was completed according to manufacturer's protocol 
(Lipofectamine 3000® [Invitrogen #L3000015]), directly onto glass cover slips (Fisher Scientific 
#12-546) in a 12 well plate (Falcon via VWR # 353043). After 2 days of incubation in a CO2 
incubator at 37ºC, cells were starved in 0.5% FBS DMEM and treated with 250µm of FeCl3 for 
24h. Cells were washed 3X with PBS++ (supplemented with 1% Ca2+ and 1% Mg2+), and fixed 
with 4% paraformaldehyde (PFA) (Sigma-Aldrich #HT5011-1CS) for 20 minutes. Cells were 
washed 1X with PBS++ and incubated in 1% glycine (Bioshop #GLN001.5) dissolved in PBS++ 
for 10 minutes, washed 3X with PBS++ and mounted onto glass slides with mounting medium 
(mixture of Prolong Anti Fade [Invitrogen #P36930] to Mounting Medium for Fluorescence with 
DAPI [Vectasheild/Vector Labs #H-1200] in a 3 to 1 ratio). Slides were observed with an LSM 
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700 confocal microscope with DAPI and FITC channels. Pixel intensity per cell was quantified 
using ImageJ software. IMARIS software was used to create representative 3D images. 
2.3.2.3 PGSK 
 Neonatal cardiomyocytes were plated onto 12 well plates with glass coverslips. Cells 
were treated with 250µM of FeCl3 for 1 and 24 hours with 0.5% FBS DMEM. 30 minutes prior to 
end of incubation, cells were incubated with 3µm of Phen Green SK, Diacete (PGSK) 
(Invitrogen #P14313) dissolved in DMSO, and incubated in a CO2 incubator at 37ºC for 30 min. 
Cells were washed 3X with PBS++, and fixed with 4% PFA for 20 minutes. Cells were washed 
1X with PBS++ and incubated in 1% glycine for 10 minutes. Cells were washed 3X with PBS++ 
and mounted onto glass slide with 1 drop mounting medium. Slides were observed with an LSM 
700 confocal microscope with DAPI and FITC channels. Pixel intensity per cell was quantified 
using ImageJ software. IMARIS software was used to create representative 3D images. 
2.3.3 Western Blot Analysis 
 Neonatal cardiomyocytes were seeded in 6 well primaria coated plates. Cells were co-
starved with 0.5% FBS DMEM and treated with 250µm of FeCl3 for 24h. 30min prior to iron 
overload conditions, cells were treated with 1µm of FOXO1 inhibitor AS1842856 (AS) 
(Emdmillipoe #506081) which was dissolved in DMSO. After treatment, wells were washed 3X 
with PBS and lysed with 200µl lysis buffer per well. Stock lysis buffer components consisted of 
50mM Tris, 0.1% SDS, 30% glycerol. Stock lysis buffer was supplemented with a protease 
inhibitor cocktail (Calbiochem via VWR #524629) [consisting of Pancreas-extract, Thermolsyin 
[Metalloprotease], Chymotrypsin, Trypsin, Papain]. 10% of ß-mercaptoethanol, and 
bromothymol blue was added to stock lysis Buffer with the protease inhibitor cocktail. Lysates 
were scraped from wells, collected and boiled for 10 minutes at 95⁰C, following cooling on ice 
and storage at -20⁰C. 
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 Samples were resolved and separated by Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Gels were run for 2 hours at 100V. Gels were immunoblotted 
onto methanol activated polyvinylidene fluoride (PVDF) membranes (BioRad #162-0177) at for 
1h at 110V. Membranes were blocked with 3% bovine serum albumin (BSA) (Bioshop 
#ALB001.1) for 1 hour on a rocker at room temperature, and incubated with primary antibody 
(AdipoR1, AdipoR2, APPL1, APPL2 and FOXO1), 1:1000 dilution in 3% BSA overnight at 4⁰C 
on a rocker. The next day, membranes were washed 3 times with wash buffer containing 1:1000 
dilutions of TWEEN 20 (Bioshop #56-40-6) and Nonidet P40 (Bioshop #NON505.500) 
detergents for 10 minute intervals at room temperature on a rocker. Subsequently, membranes 
were incubated in secondary horseradish peroxidase (HRP)-conjugated antibody (anti-rabbit or 
anti-mouse) (1:5000) (Cell Signalling #7074 and #7076, respectively) for 1 hour at room 
temperature, and then washed 3X. Membranes were incubated in Enhanced 
chemiluminescence (ECL) reagent (Bio-Rad # 1705061) for 1 minute, placed in a film cassette 
and exposed with film (GE Health Care via VWR #28906837). 
 AdipoR1, and AdipoR2 primary antibodies were kindly gifted from AstraZeneca 
(Sweden). APPL1 antibody was purchased from Antibody Immunoassay Services (AIS, Hong 
Kong). APPL2 antibody (#H00055 198-B01P) was obtained from Abnova. FOXO1 (#9454S) and 
β-actin (#4967L) antibodies were obtained from Cell Signalling.  
 Membranes were re-blotted 1X Re-Blot buffer (Emd Millipore #2504 on a rocker for 20 
minutes at room temperature. Membranes were washed 1X for 5 minutes, and re-blocked in 3% 
BSA for 30 minutes. Membranes were incubated in primary antibody (β-actin) overnight at 4⁰C. 
Developing protocol mentioned previously was followed from this point onward. 
 Band density was quantified using ImageJ Software, and normalized to appropriate β-
actin loading control.  
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2.3.4 Immunofluorescence 
 Neonatal cardiomyocytes cells were seeded onto 12 well plates with glass coverslips. 
Cells were co-starved with 0.5% or 2% DMEM and treated with the following solutions where 
appropriate: with 250µm of FeCl3 for 24h, 1µm of AS1842856 30 min prior to iron overload 
conditions, and 20µm of AdRon (AdipoGen® Life Sciences #AG-CR1-0156-M050) for 30min. 
Cells were washed 3X with PBS++, and fixed with 4% PFA for 20 minutes. Cells were washed 
1X with PBS++ and incubated in 1% glycine. Cells were washed 3X with PBS++ and 
permeabilized with 0.1% TritonX100 for 3mins. Cells were washed with PBS++, and blocked 
with 3% BSA in PBS++ for 1 hour. Slides were incubated in primary antibody (1:500 in BSA, 
PBS++) overnight at 4ºC. Slides were washed 3X with PBS++, and incubated in secondary 
antibody (1:1000 in 3% BSA, PBS++) for 1 hour at room temperature. Cells were washed 4X 
with PBS++ and mounted onto glass slide with 1 drop of mounting medium. Slides were 
observed with an LSM700 confocal microscope with DAPI and FITC channels. Pixel intensity 
per cell was quantified using ImageJ software. IMARIS software was used to create 
representative 3D images.  
 Primary antibody pAMPK (Thr 127) (#2531L) and pFOXO1 (Thr24) (#9464L) was 
obtained from Cell signalling. pP38 MAPK (pThr180/pTyr182) (#44-684G) was obtained from 
Invitrogen.  Secondary anti-rabbit Alexa Fluor 488 conjugate anti-body (#A-11008) was obtained 
from ThermoFisher Scientific (via VWR).  
2.3.5 Glucose uptake  
 Neonatal cardiomyocytes cells were seeded onto a 24 well plate, and starved with 0% 
FBS DMEM. Cells were treated with 250µm of FeCl3 for 24h and 20µm of AdRon for 1h prior to 
the end of iron overload treatments. As a positive control for glucose uptake, cells were treated 
with 100nm of insulin (Humulin #00586714) for 10 minutes. After treatment, cells were washed 
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2X with hepes buffer saline (HBS) (140nm NaCl, 20mM Hepes-Na pH=7, 5mM Kcl, 2.5mM 
MgSO4, 1.0mM CaCl2). For specific glucose uptake, 200µl of transport solution (10uM 2-Deoxy-
Glucose, 0.5uCi/ml H3 2Deoxy-Glucose in HBS [PerkinElmer #800-762-4000]) was added to 
each well, and incubated for 5 minutes. 10µM of Cytochalasin B (Sigma #C6762) was used for 
non-specific uptake. Transport solution was aspirated, and wells were washed 3X with ice-cold, 
0.9% saline solution (Bioshop #SOD002.5). 200µl of KOH (Bioshop #PHY202.500) was used to 
lyse cells. 1:20 dilution of lysate:scintillation fluid (National Diagnostics #02010193) was made 
for a total volume of 3ml. Samples with scintillation fluid were placed into scintillation vials for 
radioactive counting. Samples were corrected for protein using a bradford assay (Bio-Rad #500-
0006) which was measured at 595nm.  
2.3.6 In vivo Iron Overload Mouse Model 
 Six 8 week C57 male mice (Mus musculus) were intraperitoneally (IP) injected with 
10mg/g of ferrous form iron dextran (Santa Cruz #sc-215191) diluted in 0.9% saline for 4 weeks, 
5 days per week. Six control mice were injected with 10% dextrose (J.T. Baker#1916-01). The 
following samples were collected post-sacrifice: heart, soleus, gastrocnemius, tibialis anterior, 
liver, pancreas, spleen, adipose, brain and serum, and frozen using liquid nitrogen. Samples 
were stored in -80ºC. 
 Heart tissues were lysed with RIPA buffer (30mM Hepes pH 7.4, 2.5mM EGTA, 3mM 
EDTA, 70mM KCl, 20mM β-glycerolphosphate, 20mM NaF, 1Mm Na3VO4, 200µM PMSF, 1µM 
Pepstatin A, 10µM Et64, 1µM Leupeptin, 0.1% NP40, 0.1mM Okadaic acid) and homogenized. 
Lysates were centrifuged at 10,000RPM for 10mins at 4ºC. Protein concentration of lysates was 
measured and corrected using a colometric protein assay kit (ThermoFisher #23225). 50µg of 
protein was loaded into each well. Western blot protocol was followed as previously described.  
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 AdipoR1, and AdipoR2 primary antibodies were kindly gifted from AstraZeneca 
(Sweden). APPL1 antibody was purchased from Antibody Immunoassay Services (AIS, Hong 
Kong). APPL2 antibody (#H00055 198-B01P) was obtained from Abnova. FOXO1 (#9454S) and 
β-actin (#4967L) antibodies were obtained from Cell Signalling.  
2.3.6.1. Prussian blue staining 
 Fresh heart tissues were preserved in tissue freezing medium (Electron Miscroscopy 
Sciences# 72592) and cut into 10µm slices via cryosectioning. Cryosections were sent to 
London Health Sciences Centre at University Hospital, London, ON, for Prussian blue staining. 
2.3.6.2. Echocardiography 
 Echocardiography was performed using the Vevo2100 system (Visual Sonics) equipped 
with an MS550D transducer. Mice were lightly anesthetized using 2.0% isofluorane mixed with 
100% O2 during the time of imaging. M-mode images of the parasternal short-axis view 
at papillary level were used to calculate the cardiac systolic functions of ejection fraction, 
fractional shortening and cardiac output. Speckle-tracking cardiac strain analysis was performed 
using VevoStrain software and movie files acquired were from the B-mode and M-mode view. 
All parameters were averaged over at least 3 cardiac cycles for analysis.  
3.3.7. Statistical Analysis 
 Statistical analysis between two groups was done using an unpaired two-tailed t-test. P 
values less than 0.05 were accepted as significant.  
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2.4 Results 
2.4.1. Characterizing intracellular iron overload and cell viability in NeoCM 
 To characterize an iron overload model in neonatal cardiomyocytes (NeoCM), cells were 
treated with 250µM of ferric iron for 0, 1 and 24h. At 30min before prior to the end of treatment 
time, 3µm of Phen Green™ SK (PGSK)  - a fluorescent indicator - was added to cells. Upon the 
presence of heavy metals, PGSK becomes quenched, resulting in a decrease in green 
fluorescence. This was shown by a gradual decrease in PGSK fluorescence at 1h of iron 
treatment time compared to 0h control. Moreover, a significant decrease of PGSK fluorescence 
was observed at 24h compared to 0h of iron treatment (Figure 2.1 A-C). Iron overload induced 
iron response element (IRE) activation was also investigated in NeoCM to characterize 
intracellular iron regulation. Cells were transfected with a plasmid which encodes a ferratin 
promoter containing an IRE hairpin stem loop. Upon activation of IRE via iron overload 
conditions, cyan fluorescent protein (CFP) is transcribed and acts as a detectable readout of 
IRE activity. Following 24h treatment of iron, a 3.5 fold increase in CFP was observed in iron 
overload conditions compared to control (Figure 2.1 D-F). Together, these results indicate iron 
can directly enter NeoCM, and activate intracellular iron regulatory processes.  
 Cell viability was confirmed using an MTT assay. This assay measures cell metabolic 
activity by measuring NADPH (Nicotinamide adenine dinucleotide phosphate)-dependent 
cellular oxidoreductiase enzymes which are known to reduce MTT dye. Following this reaction, 
the resulting product becomes detectable at 595nm. NeoCM were treated with 0, 100, and 
250µM of iron overload for 24h, following the addition of 5mg/ml of MTT 5h prior to end of 
incubation. Results show no change in cell viability with 100µM and 250µM iron overload 
compared to control conditions (Figure 2.1).  
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Figure 2.1: Characterizing intracellular iron overload ex vivo.  
(A-C) Iron overload conditions quenched PGSK probe over time, resulting in less green 
fluorescence. NeoCM were treated with 250µM of FeCl3 for 0, 1 and 24h. 30min prior to end of 
incubation, 3µM of PGSK probe was added to cells. Green fluorescence was observed via FTIC 
channels by confocal microscopy (n=3). A) 2D representative image taken using ZEN software 
(Scale bar: 1µm). B) 3D representative images created using IMARIS software (Scale bar: 
5µm). C) 3-5 fields of view were taken per condition. All cells in field of view were traced and 
quantified using ImageJ software. Mean intensity values per cell were averaged and plotted for 
analysis. Statistical analysis was compared to 0h. (* = P < 0.05). Error bars display standard 
error of the mean.  
(D-F) Increased iron response element activity was observed under iron overload 
conditions. NeoCM were transfected with IRE-CFP plasmid, and treated with 250µM of FeCl3 
for 24h (n=3). Transcribed cyan fluorescent protein was observed via FTIC channels by 
confocal microscopy. D) 2D representative image taken using ZEN software (Scale bar: 1µm). 
E) 3D representative images created using IMARIS software (Scale bar: 5µm). F) 3-5 fields of 
view were taken per conditions. All cells in field of view were traced and quantified using ImageJ 
software. Mean intensity values per cell were averaged and plotted for analysis. Statistical 
analysis was compared to IRE-CFP. (* = P < 0.05). Error bars display standard error of the 
mean.  
(G) No significant change in cell viability was observed under iron overload conditions of 
varying concentrations. NeoCM were treated with 0, 100 and 250µM of FeCl3 24h. 5h prior to 
end of incubation, 5mg/ml of MTT was added to cells. Absorbance was measured at 595nm, 
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and absorbance values were normalized to average of controls (n=3). Statistical analysis was 
compared to control. Error bars display standard error of the mean.  
 
2.4.2 Iron overload induced adiponectin resistance via adiponectin sensitivity in NeoCM 
 Following the characterization of intracellular iron overload in NeoCM, adiponectin 
sensitivity was examined to investigate iron overload induced adiponectin resistance. This was 
examined by AdRon induced adiponectin signalling via pAMPK and pP38 MAPK signalling 
molecules. Neonatal cardiomyocytes were treated with iron overload for 24h, followed by AdRon 
treatment for 30min prior to end of iron overload treatment time. Immunofluorescence featuring 
pAMPK and pP38 MAPK antibodies was used to investigate changes in adiponectin signalling 
under these conditions. A significant increase in pAMPK was observed in AdRon conditions 
compared to basal levels. However, when AdRon was added to iron overload conditions, a 
significant decrease in pAMPK stimulation was observed compared to AdRon in normal 
conditions (Figure 2.2 A-C). The same trend was also confirmed with pP38 (Figure 2.2 D-F). 
AdRon stimulated glucose uptake - another method of adiponectin action -  was used to 
investigate any adiponectin resistance occurring under iron overload conditions. NeoCM cells 
treated with iron overload conditions, and later stimulated with AdRon for 30min prior to end of 
iron overload treatment. This resulted in an increase in glucose uptake was observed in AdRon 
conditions, while iron overload conditions showed no effect compared to basal levels. Moreover, 
when AdRon was added to iron overload conditions, a significant decrease in glucose uptake 
was observed compared to AdRon in normal conditions (Figure 2.2 G). Overall, these results 
show iron overload induced adiponectin resistance via pAMPK and pP38 stimulation, as well as 
via glucose uptake in NeoCM.  
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Figure 2.2: Adiponectin resistance was observed via AdRon induced adiponectin 
signaling (pAMPK and pP38 MAPK) and AdRon stimulated metabolism via glucose 
uptake.  
(A-C) Iron overload decreased adiponectin sensitivity by AdRon induced pAMPK 
stimulation. NeoCM were treated with 250µM of FeCl3 for 24h, and 20µM AdRon for 30min 
prior to end of treatment time. Cells were incubated in pAMPK (Thr172) primary antibody, and 
subsequently incubated in Alexa 488 secondary antibody. Green fluorescence was observed via 
FTIC channels by confocal microscopy (n=3). A) 2D representative image taken using ZEN 
software (Scale bar: 1µm). B) 3D representative images created using IMARIS software (Scale 
bar: 5µm). C) 3-5 fields of view were taken per condition. All cells in field of view were traced 
and quantified using ImageJ software. Mean intensity values per cell were averaged, and 
normalized to appropriate control (Raw mean intensity values - Control: 8.288203, AdRon: 
30.33062, Iron: 51.51557, Iron+AdRon: 19.31903). Statistical analysis was compared to control. 
(* = P < 0.05) and AdRon conditions (# = P < 0.05). Error bars display standard error of the 
mean. 
(D-F) Iron overload decreased adiponectin sensitivity by AdRon induced pP38 MAPK 
stimulation. NeoCM were treated with 250µM of FeCl3 for 24h, and 20µM AdRon for 30min 
prior to end of treatment time. Cells were incubated in pP38 MAPK (Thr180/Tyr182) primary 
antibody, and subsequently incubated in Alexa 488 secondary antibody. Green fluorescence 
was observed via FTIC channels by confocal microscopy (n=3). D) 2D representative image 
taken using ZEN software (Scale bar: 1µm). E) 3D representative images created using IMARIS 
software (Scale bar: 5µm). F) 3-5 fields of view were taken per condition. All cells in field of view 
were traced and quantified using ImageJ software. Mean intensity values per cell were 
averaged, and normalized to appropriate control (Raw mean intensity values – Control: 
32.29259, AdRon: 55.0053, Iron: 71.82387, Iron+AdRon: 38.91023). Statistical analysis was 
compared to control. (* = P < 0.05) and AdRon conditions (# = P < 0.05). Error bars display 
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standard error of the mean.  
(G) Iron overload decreased adiponectin signalling by AdRon induced glucose uptake. 
NeoCM were treated with 250µm of FeCl3 for 24h, and 20µM of AdRon 1h prior to end of 
treatment time. As a positive control, NeoCM were stimulated with 100nM of insulin for 10 
minutes. Cells were treated with radioactive H3 2 deoxy-D-(3H) – glucose for 5min. Cells were 
lysed, collected for scintillation counting, and corrected for protein concentration. 
(n=4).Statistical analysis was compared to control (* = P <0.05) and compared to AdRon (# = P 
<0.05). Error bars display standard error of the mean.  
 
2.4.3 Iron overload regulation by FOXO1 in NeoCM 
 Next, it was proposed that iron overload regulation is controlled via FOXO due to 
analysis of previous literature. FOXO1 regulation itself is dependent on post-translational 
modifications which in turn result in a change in cellular localization. Iron overload regulation by 
FOXO1 was investigated by immunofluorescence featuring total FOXO1 and pFOXO1 (Thr24). 
NeoCM cells were treated with iron overload for 24h, fixed and stained with either total FOXO1 
and pFOXO1 (Thr24). Results showed a significant increase in total FOXO1 expression by a 3.5 
fold (Figure 2.3 A-C). Moreover, a 30 fold increase in pFOXO1 (Thr24) was observed 
compared to basal levels (Figure 2.3 D-F). Overall, these results show that iron overload 
causes a significant increase in cytoplasmic localization via an increase in pFOXO1. Moreover, 
iron overload also caused a significant increase in overall protein expression shown by an 
increase in total FOXO1.  
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Figure 2.3: Iron overload regulation by FOXO1.  
(A-C) Iron overload increased FOXO1 expression. NeoCM were treated with 250µM of FeCl3 
for 24h. Cells were incubated in total FOXO primary antibody, and subsequently incubated in 
Alexa 488 secondary antibody. Green fluorescence was observed via FTIC channels by 
confocal microscopy (n=3). A) 2D representative image taken using ZEN software (Scale bar: 
1µm). B) 3D representative images created using IMARIS software (Scale bar: 5µm). C) 3-5 
fields of view were taken per condition. All cells in field of view were traced and quantified using 
ImageJ software. Mean intensity values per cell were averaged, and normalized to control. 
Statistical analysis was compared to control. (* = P < 0.05). Error bars display standard error of 
the mean.  
(D-F) Iron overload increased pFOXO1 (Thr24) regulation. NeoCM were treated with 250µM 
of FeCl3 for 24h. Cells were incubated in pFOXO1 (Thr24) primary antibody, and subsequently 
incubated in Alexa 488 secondary antibody. Green fluorescence was observed via FTIC 
channels by confocal microscopy (n=3). D) 2D representative image taken using ZEN software 
(Scale bar: 1µm). E) 3D representative images created using IMARIS software (Scale bar: 
5µm). F) 3-5 fields of view were taken per condition. All cells in field of view were traced and 
quantified using ImageJ software. Mean intensity values per cell were averaged, and 
normalized to control. Statistical analysis was compared to control. (* = P < 0.05). Error bars 
display standard error of the mean.  
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2.4.4 Iron overload induced adiponectin resistance regulation by FOXO1 in NeoCM 
 After confirming FOXO1's a role in iron overload regulation, the potential regulation of 
iron overload induced adiponectin resistance by FOXO was examined. This was investigated 
using the FOXO inhibitor, AS1842856, which prevents FOXO-DNA binding, and ultimately 
preventing transcription. Anti-pAMPK (Thr172) immunofluorescence analysis was used to 
investigate the effects of iron overload induced adiponectin resistance regulation by FOXO 
inhibition. NeoCM were treated with AS1842856 30min prior to iron overload for 24h, following a 
30min AdRon treatment prior to end of iron overload. As shown previously, AdRon increased 
pAMPK stimulation significantly compared to control, however this affect was reduced upon iron 
overload conditions. Further, AS1842856 treatment had no significant effect on pAMPK levels. 
However, when combined with iron and AdRon, AS1842856 treatment alleviated iron overloads' 
effects on AdRon, resulting in a significant increase of pAMPK back to AdRon only conditions. 
This was also shown by a significant increase in pAMPK in iron, AdRon and AS1842856 
conditions compared to iron and AdRon conditions only (Figure 2.4 A-C). Overall, this effect 
confirms FOXO1's role in iron overload induced adiponectin resistance regulation.  
 
 
 
 
 
 
 
 
34 
 
 
Figure 2.4: Iron overload induced adiponectin resistance regulation by FOXO1. NeoCM 
were treated with 250µM of FeCl3 for 24h, and 20µM of AdRon for 30min prior to end of 
treatment time. 30min prior to iron incubation, cells were treated with 1µM of FOXO inhibitor, 
AS1842856.  Cells were incubated in pAMPK (Thr172) primary antibody, and subsequently 
incubated in Alexa 488 secondary antibody. Green fluorescence was observed via FTIC 
channels by confocal microscopy (n=3). A) 2D representative image taken using ZEN software 
(Scale bar: 1µm). B) 3D representative images created using IMARIS software (Scale bar: 
5µm).  C) 3-5 fields of view were taken per condition. All cells in field of view were traced and 
quantified using ImageJ software. Mean intensity values per cell were averaged, and 
normalized to control. Statistical analysis was compared to control (* = P < 0.05), AdRon (# = P 
< 0.05) or Iron+AdRon ($ = P < 0.05). Error bars display standard error of the mean.  
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2.4.5 Iron overload induced adiponectin resistance via adiponectin signalling in NeoCM 
 Next, iron overload induced adiponectin resistance was investigated by examining 
adiponectin receptor levels as well as other downstream targets of adiponectin signalling. 
FOXO1 inhibitor, AS1842856, was used to examine any changes in gene expression of 
adiponectin signalling molecules, and to observe its effects on iron overload induced 
adiponectin resistance regulation. NeoCM were treated with AS1842856 30min prior to 24h iron 
overload conditions. Western blot analysis was used to examine the expression of the following 
proteins: AdipoR1, APPL1, AdipoR2 and APPL2. Under iron overload conditions, a significant 
decrease in AdipoR1 and APPL1 was observed. Additionally, APPL2 also showed a decrease in 
expression by approximately 50% compared to control levels. However, AdipoR2 gene 
expression did not change under iron overload conditions. Furthermore, no changes in gene 
expression in AdipoR1, APPL1, AdipoR2 and APPL2 were evident using FOXO1 inhibitor, 
AS1842856 (Figure 2.5 A-E). Therefore, no further alleviatory effect with iron and AS1842856 
conditions were observed. Overall, this data confirms iron overload induced adiponectin 
resistance occurs via reduced adiponectin signalling molecule expression levels. Conversely, 
FOXO1 may not play a regulatory role in iron overload induced adiponectin resistance 
regulation on the level of adiponectin signalling protein expression. 
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Figure 2.5: Iron overload induced adiponectin resistance regulation by FOXO via 
adiponectin signalling. NeoCM were treated with 250µM of FeCl3 for 24h, and 1µM 
AS1842856 30min prior to iron overload incubation. Cells were lysed, proteins of interest were 
analyzed by Western blotting. Proteins of interest were tagged with the following primary 
antibodies: AdipoR1, APPL1, AdipoR2, APPL2 and β-actin, which were subsequently tagged 
with HRP-conjugated secondary antibodies (n=4/7). A) Representative western blots of 
AdipoR1, APPL1, AdipoR2, APPL2 and β-actin. (B-E) Quantitative representation of AdipoR1, 
APPL1, AdipoR2 and APPL2. Western blot band intensity was quantified using ImageJ 
software, normalized to β-actin, and further normalized to control. Statistical analysis was 
compared to control conditions (* = P < 0.05). Error bars display standard error of the mean.  
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2.4.6. In vivo iron overload induced adiponectin resistance in the heart 
 Cardiac iron overload induced adiponectin resistance was further examined via an in 
vivo iron overload mouse model. Male C57 mice of 8 weeks were IP injected with 10mg/g of 
ferrous iron for 4 weeks, 5 days per week. To characterize the presence iron overload in this 
mouse model, Prussian blue staining of heart tissue cryosections was conducted. An increase 
in Prussian blue staining was observed in iron overload mice compared to control mice, 
confirming the ability of iron to reach the target tissues (Figure 2.6 A-B).  
 Next, western blot analysis was used to examine the protein expression of AdipoR1, 
APPL1, AdipoR2, APPL2 and FOXO1 (Figure 2.7 A-F). No changes were evident in AdipoR1 
and APPL1 expression. However, a significant increase by approximately two fold was seen in 
AdipoR2. Conversely, a very significant reduction in APPL2 by approximately 90% was seen in 
iron overload mice compared to control. No significant changes in FOXO expression were 
evident in iron overload mice compared to control. In conclusion, this model suggests altered 
adiponectin regulation via a significant reduction in APPL2 expression. 
 
2.4.6.1. Echocardiography  
 Further characterization and analysis by echocardiography was used to investigate any 
cardiac dysfunction in iron overload conditions. Overall body weight was significantly reduced in 
iron overload (Figure 2.7 A). Additionally, a significant decrease in heart rate (Figure 2.7 B) 
and cardiac output (Figure 2.7 D) was also observed. No significant changes were seen in 
posterior wall thickness (Figure 2.7 B), ejection fraction, fractional shortening, left ventricular 
(LV) mass and stroke volume (Figure 2.7 E-H). Furthermore, no changes in strain peak 
(PK)/strain rate were observed (Figure 2.7 I-J), however a significant increase was observed in 
maximal opposing wall delay strain/maximal opposing wall delay (Figure K-L). In conclusion, 
results indicate cardiac dysfunction in iron overload mice compared to control.  
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Figure 2.6: Characterizing iron overload in vivo. Iron overload mice display increased 
amount of Prussian blue staining compared to control. 8 week C57 male mice were IP injected 
with 10mg/g of ferrous iron. Heart tissue cryosections were stained with prussian blue and 
analyzed by histopathology. (n=3). A) Representative image of control mice. B) Representative 
image of iron overload mice. Original magnification X100 for all micrographs. 
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Figure 2.7: Iron overload altered adiponectin signalling in vivo via changes in expression 
of adiponectin signalling proteins. 8 week C57 male mice were IP injected with 10mg/g of 
ferrous iron. Heart tissues were lysed, proteins of interest were analyzed by Western blotting. 
Proteins of interest were tagged with the following primary antibodies: AdipoR1, APPL1, 
AdipoR2, APPL2, total FOXO1 and β-actin, which were subsequently tagged with HRP-
conjugated secondary antibodies (n=6). A) Representative western blots of AdipoR1, APPL1, 
AdipoR2, APPL2, total FOXO1 and β-actin. (B-F) Quantitative representation of AdipoR1, 
APPL1, AdipoR2, APPL2 and total FOXO1. Western blot band intensity was quantified using 
ImageJ software, normalized to β-actin, and further normalized to control. Statistical analysis 
was compared to control conditions (* = P < 0.05). Error bars display standard error of the 
mean. Note: For uncut Western blots, see Appendix A: A3. 
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Figure 2.8: Iron overload induced mice display cardiac dysfunction via 
echocardiography. Figures display representative graph of A) body weight, B) heart rate, C) 
posterior wall thickness, D) cardiac output, E) ejection fraction, F) fractional shortening, G) LV 
mass, H) stroke volume, I) strain PK, J) strain rate  K) maximal opposing wall delay strain, and 
L) maximal opposing wall delay strain rate. M-mode images of the parasternal short-axis view 
at papillary level were used to calculate the cardiac systolic functions of ejection fraction, 
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fractional shortening and cardiac output. Speckle-tracking cardiac strain analysis was performed 
using VevoStrain software (n=4). All parameters were averaged over at least 3 cardiac cycles 
for analysis. Statistical analysis was compared to control conditions (* = P < 0.05). Error bars 
display standard error of the mean.  
 
2.5. Discussion 
2.5.1. Iron accumulates in NeoCM and activates IREs 
 The validation of iron overload in NeoCM was essential prior to examining the possibility 
of iron overload induced adiponectin resistance. PGSK, a green-fluorescent indicator, was used 
to characterize intracellular iron in a time-dependent manner. When iron binds to PGSK, green-
fluorescence becomes quenched111. Results indicate that iron overload quenches, which was 
observed by a gradual time dependent decrease in green fluorescence from 0h to 24h (Figure 
2.1 A-C). An IRE-CFP reporter construct was also used to confirm functional effectiveness of 
iron delivered to cells. Iron overload conditions activated IRE regulatory elements, suggesting 
an increase in ferritin regulation and thus confirming iron overload conditions in NeoCM  
112(Figure 2.1 D-F). Moreover, the cell viability of iron overload induced NeoCM was examined 
with an MTT assay. This assay is based on the conversion of MTT into formazan crystals by 
NAD(P)H-dependent cellular oxidoreductase enzymes in living cells, which is a direct measure 
of mitochondrial activity, and is commonly used as a readout of cell viability113. As no significant 
change in cell viability was observed using 100µM and 250µM of FeCl3 during 24h, a 
concentration of 250µM was used to induce iron overload in future experiments (Figure 2.1 G); 
a concentration previously used in cell culture iron overload studies114. To conclude, iron 
overload conditions in NeoCM did not induce cell death. Moreover, PGSK and IRE-CFP assays 
confirm the ability of iron to enter the cell, as well as initiate changes in iron regulatory response 
elements, respectively.  
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2.5.2 Iron overload induced adiponectin resistance via adiponectin sensitivity and action in 
NeoCM 
 AMPK and P38 MAPK are down-stream targets of AdipoR1 and AdipoR2, and are both 
known to be stimulated by adiponectin53 and AdRon77. In NeoCM, stimulation of pAMPK and 
pP38 via AdRon was used as a direct readout of adiponectin sensitivity. Using 
immunofluorescence based pAMPK and pP38 detection, the investigation of iron overload 
induced adiponectin resistance was examined by observing changes in levels of green 
fluorescence (Figure 2.2 A-C and 2.2 D-F). pAMPK and pP38 levels significantly increased with 
AdRon as expected. This confirms AdRon's ability to stimulate adiponectin signalling in this 
experimental model77. However, combined with iron overload, AdRon stimulated pAMPK and 
pP38 levels were significantly reduced. This lack in adiponectin signalling due to iron overload 
conditions is the first evidence of iron overload induced adiponectin resistance in NeoCM. This 
is supported by a previous study whereby adiponectin resistance in chronic heart failure has 
been characterized by a decrease in pAMPK levels84. Somewhat unexpectedly, pAMPK and 
pP38 levels also increased in iron overload only conditions. pAMPK mediates majority of all 
aspects of cellular regulation, therefore cross-talk between various signalling pathways are likely 
initiated by pAMPK115. For instance, iron has been previously shown to activate pAMPK in HF 
diet mice, suggesting iron plays a role in the regulation of pAMPK glucose metabolism116. 
Additionally, iron has also been shown to regulate pP38 activation via various inflammatory 
pathways117. To conclude, iron overload induced adiponectin resistance. 
 Glucose uptake, another direct readout of adiponectin action, was also used to examine 
iron overload induced adiponectin resistance in NeoCM. Adiponectin and AdRon have been 
previously shown to stimulate glucose uptake on multiple occasions16,77. Previous studies have 
also used glucose uptake as a method to investigate the mechanisms of adiponectin 
resistance84. As expected, AdRon significantly increased glucose uptake in NeoCM compared 
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to control conditions (Figure 2.2 G). Moreover, no change in glucose uptake was observed in 
iron overload, as compared to control conditions. However, iron overload and AdRon conditions 
together reduced glucose uptake compared to AdRon only conditions. This data further 
supports that iron overload conditions suppress AdRon action via glucose uptake84, suggesting 
iron overload induced adiponectin resistance. 
2.5.3 FOXO1 regulates iron overload in NeoCM 
 Iron overload induced adiponectin resistance in the heart is a phenomenon that is poorly 
characterized and thus its mechanisms are also poorly understood. I hypothesized that FOXO1 
is involved in iron overload induced adiponectin resistance regulation. Thus, it was necessary to 
first characterize FOXO1's role in iron overload conditions. This was done by examining FOXO1 
expression and pFOXO1 stimulation under iron overload via immunofluorescence. An increase 
in total FOXO1 expression, and also pFOXO1 stimulation was evident under iron overload 
(Figure 2.3 A-C and 2.3 D-F). This is significant as iron has been previously shown to modulate 
the post-translational profiles of FOXO1 by specifically regulating its phosphorylation via 
reactive oxygen species (ROS) production118,119,120.  
2.5.4. FOXO1 regulates iron overload induced adiponectin resistance in NeoCM 
 After characterizing iron's ability to regulate FOXO1, the role of FOXO1 mediated iron 
overload induced adiponectin resistance was investigated by examining adiponectin sensitivity 
via adiponectin signalling. FOXO1 mediated regulation of iron overload induced adiponectin 
resistance was examined using a FOXO1 inhibitor, AS1842856, which works by directly binding 
to active FOXO1121. First, anti-pAMPK immunofluorescence was used to investigate the role of 
FOXO1 in iron overload induced adiponectin resistance (Figure 2.4 A-C). As previously shown, 
iron overload induced adiponectin resistance occurs by reduced pAMPK stimulation in iron and 
AdRon conditions compared to AdRon only conditions. AS1842856 had no affect on pAMPK 
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stimulation compared to control. However, when added to iron and AdRon conditions, pAMPK 
levels were similar to AdRon only conditions. This suggests that FOXO1 plays a role in 
regulating iron overload induced adiponectin resistance, and when FOXO1 is inhibited, AdRon 
stimulated adiponectin signalling is alleviated from iron overload's affects. This data is 
supported by iron overload induced adiponectin resistance regulation in adipoctyes122. Previous 
literature has suggested the regulation of iron overload induced adiponectin resistance via 
FOXO1 transcription factor regulation122.  
 Moreover, FOXO1 inhibitor AS1842856 was used to investigate FOXO1 mediated iron 
overload induced adiponectin resistance via regulation of critical adiponectin signalling 
molecules (Figure 2.5 A-E). Under iron overload conditions, a significant decrease in AdipoR1 
and APPL1 was observed. APPL2 also showed insignificant decrease in expression compared 
to control levels. Moreover, no significant changes in AdipoR2 gene expression were observed. 
These findings support the iron overload induced adiponectin resistance hypothesis via 
adiponectin signalling molecule gene expression. This is supported by previous literature 
whereby adiponectin resistance is observed by a decreased in AdipoR184, as well as APPL1 - 
an AdipoR1 and AdipoR2 stimulator54. Furthermore, no changes in gene expression of 
AdipoR1, APPL1, AdipoR2 and APPL2 were evident using FOXO1 inhibitor, AS1842856 
(Figure 2.5 A-E). Therefore, there was no further alleviatory effect provided by AS1842856, 
which was previously seen with pAMPK (Figure 2.4 A-C). FOXO1 may not play a regulatory 
role in iron overload induced adiponectin resistance regulation on the level of adiponectin 
signalling protein expression as expected, and it may be regulated by an alternate mechanism 
other than FOXO1. Overall, no definitive conclusions can be made regarding the regulation of 
iron overload induced adiponectin resistance on the level of adiponectin signalling protein 
expression, and further investigations are required to elucidate the exact mechanisms. 
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However, these results support my hypothesis, whereby FOXO1 regulates iron overload 
induced adiponectin resistance via adiponectin sensitivity. 
2.5.5. Iron overload altered myocardial adiponectin signalling in mouse model 
 After characterizing iron overload induced adiponectin resistance in NeoCM, an in vivo 
iron overload mouse model was investigated to further examine the presence of adiponectin 
resistance in the heart. Iron overload induced adiponectin regulation has not been well-studied 
in IP injected iron overload mouse models.  
 First, Prussian blue staining was used to characterize cardiac iron accumulation in iron 
overload mice. Prussian blue staining utilizes a histochemical reaction involving hydrochloric 
acid and potassium ferrocyanide. Following the release of FeCl3 with hydrochloric acid, the 
combination with ferrocyanide results is a blue colour, also known as Prussian blue123. 
Ultimately, Prussian blue staining displayed cardiac iron accumulation in iron overload mice 
compared to control mice, confirming an iron overload model (Figure 2.6 A-B).  
 Next, Western blot analysis of AdipoR1, APPL1, AdipoR2 and APPL2 was conducted in 
order to examine iron overload induced changes in gene expression. A reduction in AdipoR1 
and APPL1 was not evident in iron mice compared to control mice as expected (Figure 2.7 A-
C). Moreover, an increase observed in AdipoR2 and a significant loss in APPL2. As APPL2 
competitively binds to APPL1 to compete for AdipoR1 and AdipoR2 binding, a loss in APPL2 
may suggest an up-regulation in adiponectin receptor action via APPL1 activation58. Previous 
literature supports the potential of iron overload increased adiponectin signalling via an increase 
in adiponectin monomer in dietary iron overload mice122. Conversely, another study examining 
iron fed mice showed reduced adiponectin compared to control mice, while also showing that 
mice with hereditary hemochromatosis displayed increased levels of adiponectin122. Therefore, 
further investigation is required to understand iron overloads role in adiponectin signalling 
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regulation in in vivo models. Moreover, adiponectin signalling regulation was also observed via 
Western blot analysis by observing FOXO1 expression levels. No changes in FOXO1 
expression were evident in iron overload mice compared to control, thus no strong conclusions 
on adiponectin signalling can be made and require further investigation. 
 Further analysis of heart tissue adiponectin levels in IP injected iron overload mice 
should be assessed in order to confirm these findings. This model does not confirm adiponectin 
resistance hypothesis as seen in NeoCM, however it does suggest that adiponectin regulation is 
altered by iron overload conditions. This level of altered adiponectin action by iron overload is a 
phenomenon that involves further investigation. Thus, I am proposing iron overload induced 
adiponectin regulation is dependent on the level and timing of iron overload. Although iron 
overload has been characterized in both ex vivo and in vitro models, the level of iron overload is 
something that is greatly misunderstood. As mentioned previously, earlier studies have 
confirmed the presence both iron overload induced adiponectin resistance, as well as iron 
overload induced adiponectin signalling up-regulation. Therefore, this balance of adiponectin 
action may greatly depend on the severity of iron overload. For instance, it is well characterized 
that adiponectin is cardioprotective against heart disease108,109,110, however several cases have 
suggested otherwise8,9,124. Therefore, it is further hypothesized that adiponectin resistance could 
occur under mild instances of iron overload while an up-regulation of adiponectin signalling is 
required to alleviate the affects of chronic iron overload. To conclude, understand the regulation 
of iron overload on a spectrum, rather than an "on and off" state, is essential to comprehend 
iron overload's effects on cardiac metabolism. 
2.5.5.1. Iron overload causes altered cardiac functioning 
 Further characterization and analysis of iron overload induced altered cardiac function 
was examined by echocardiography. First, we observed that a significant decrease in overall 
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body weight was evident in iron overload mice. Previous literature has indicated a link between 
hemochromatosis patients and weight loss. Moreover, iron overload mice have also previously 
shown to have reduced body weight in iron fed mice, but in mice not with hereditary 
hemochromatosis122. Moving onto cardiac function, iron overload mice showed a significant 
decrease in heart rate and cardiac output, which could be explained as a compensatory 
mechanism for the reduced trend in LV mass. These results are consistent with clinical cases, 
whereby young thalassemia patients were also found to have a decreased heart rate, which 
they proposed as a potential contributor to cardiac disease125. No significant changes were seen 
in posterior wall thickness, ejection fraction, fractional shortening, and stroke volume. These 
results are similar to a study whereby mice were IP injected weekly with iron-dextran for 13 
weeks. They found no changes in systolic function, left ventricular wall thickness or diastolic 
dimension were observed in iron mice via echocardiography126. Moreover, another group 
examined genetic β-thalassemia mice, whereby they found cardiac function was conserved 
between β-thalassemia and control mice, indicated by a constant stroke volume127. No changes 
in strain PK/strain rate, also described as myocardial deformation, were indentified in this iron 
overload mouse model. However, a previous study found reduced myocardial deformation in 
patients with β-thalassemia major, indicating altered cardiac functioning in iron overload 
patients128. Furthermore, the impact of iron overload on myocardial deformation rate is a 
concept which requires future analysis. A significant increase in maximal opposing wall delay 
strain/maximal opposing wall delay in iron overload mice reveal early cardiac dysfunction. A 
study examining echocardiography in patients with thalassemia observed wall motion 
abnormalities in patients with iron overload as well129. In conclusion, results indicate altered 
cardiac functioning in iron overload mice shown by reduced heart rate, cardiac output, a 
maximal opposing wall delay - all of which are indicators of myocardial iron overload, a 
contributor to cardiomyopathy and heart failure130. 
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Chapter 3: The investigation of iron overload induced adiponectin 
resistance in skeletal muscle, featuring in vitro L6 skeletal muscle 
cells and an in vivo iron overload mouse model 
3.1 Preface 
 The relationship between metabolic syndrome and diabetes has been extensively 
investigated. Iron overload-induced diabetes has also been well characterized; however the 
mechanistic regulation of iron overload induced diabetes - and the role of adiponectin regulation 
in iron overload disease - is currently unknown. Moreover, the investigation of iron overload 
induced adiponectin resistance mediated by FOXO1 transcription factor regulation has not been 
established in skeletal muscle. Firstly, in vivo L6 myoblasts treated with iron were used to 
examine iron overload induced adiponectin resistance in skeletal muscle. Adiponectin 
resistance was characterized by reduced AdipoR1, APPL1 and adiponectin expression, as well 
as reduced fAd stimulated AMPK phosphorylation, and AdRon stimulated glucose uptake. The 
regulation of iron overload induced adiponectin resistance by FOXO1 was confirmed via 
pFOXO1 cytoplasmic localization under iron overload conditions, in addition to the alleviation of 
iron overload inhibited AdRon glucose uptake via the inhibition of FOXO1. Secondly, an in vivo 
animal model showed adiponectin signalling was up-regulated in iron overload mice skeletal 
muscle, as well as altered glucose metabolism. In conclusion, these results suggest a 
dysregulation of adiponectin action in iron overload conditions, which provides more 
mechanistic and functional insight for iron overload induced diabetes regulation.  
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3.2 Introduction  
 The prevalence of diabetes in metabolic syndrome has shown a strong correlation in 
previous research12,13,15-,32,131,132. Diabetes arises from the inability to produce or respond to 
insulin, causing abnormal carbohydrate metabolism and elevated blood sugar levels11. This 
regulation of glucose in diabetes has been previously linked to regulation by adiponectin133,78,131. 
Adiponectin is a therapeutic target for diabetes treatment, due to its anti-diabetic properties42. 
Reduced adiponectin plasma concentrations are observed in the development of diabetes,32 
and decreased adiponectin levels are associated with the onset of insulin resistance42,44. In 
addition, several studies proposed a phenomenon known as adiponectin resistance59, 134. This 
can be defined as subnormal biological response to normal adiponectin concentrations.  
Adiponectin resistance occurs under stress conditions; however, the physiological significance 
and mechanistic regulation of this novel phenomenon in skeletal muscle currently remain 
unclear. 
 The link between iron overload and diabetes has been recently well characterized102. 
Iron is known to play a role in regulating glucose metabolism103, as well as insulin resistance 
regulation104. However, the mechanistic regulation regarding the underlying molecular 
mechanisms via adiponectin currently remains misunderstood102. Moreover, the phenomenon of 
iron overload induced adiponectin resistance in skeletal muscle has not been well researched. 
Thus, this chapter aims to investigate the presence iron overload induced adiponectin 
resistance in skeletal muscle, and further the understanding of this mechanism though its 
potential regulation by the transcription factor FOXO1. Changes in adiponectin signalling gene 
expression and adiponectin sensitivity will be studied. Overall, these hypotheses will be 
examined using in vivo L6 myoblasts and the skeletal muscle of an iron overload with in vivo 
mouse model.  
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3.3 Materials and Methods 
3.3.1 L6 Skeletal Muscle Culturing 
 L6 (Rattus Norvegicus) skeletal muscle myoblasts were maintained in 10% FBS AMEM 
(Wisent Inc. #310-010-CL) and 1% Antibiotic-Antimycotic (Gibco Life technologies #15240-602). 
Cells were grown in 75cm² flasks (Falcon via VWR #353136), and were split when confluency 
reached 70%. When confluent conditions were reached, 3ml of trypsin (Wisent Inc. #325-043) 
was added to 75cm² flasks which were placed in a 37⁰C incubator for 2 minutes. Flasks were 
gently tapped, and floating cells were collected and neutralized with 3ml of 10% FBS AMEM in a 
15ml conical tube. Cells were spun down for 5 minutes at 2000 RPM and respuspened in 10ml 
of 10% FBS AMEM. 10% of total suspension was used for further culturing and plating. 
3.3.2. Characterizing intracellular iron: 
3.3.2.1. IRE-CFP 
 IRE-CFP Assay was completed as previously described with the following modifications. 
After transfection, cells were incubated in a CO2 incubator at 37ºC for 2 days. Then, cells were 
co-starved in 0.5% FBS AMEM and treated with 250µm of FeCl3 for 24h, following fixation and 
visualization with an LSM 700 confocal microscope with DAPI and FITC channels. Pixel 
intensity was quantified using ImageJ software. IMARIS software was used to create 
representative 3D images. 
3.3.3 Western Blot Analysis 
 L6 myoblasts were seeded in 6 well plates (Falcon #353046). Cells were starved with 
0.5% FBS AMEM, and treated with 1µm of AS1842856 for 30min. Cells were then treated with 
250µm of FeCl3 for 24h. 30min prior to the end of iron overload conditions, myoblasts were 
treated with 20µm of AdRon for 30min. Cell lysate and western blot protocol mentioned 
previously was followed this point onward. 
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 Membranes were blotted for the following proteins: AdipoR1, AdipoR2 and APPL1. 
AdipoR1, and AdipoR2 primary antibodies were kindly gifted from AstraZeneca (Sweden). 
APPL1 antibody was purchased from Antibody Immunoassay Services (AIS, Hong Kong). β-
actin (#4967L) antibody was obtained from Cell Signalling. 
3.3.4 Immunofluorescence 
 L6 myoblasts were seeded onto 12 well plates with glass coverslips. Cells were starved 
with 0.5% AMEM and treated with the following solutions where appropriate: with 250µm of 
FeCl3 for 0, 0.5, 1, 2, 4 or 24h, 100nm of insulin for 15min, 20µm of AdRon for 30min or 5µg/ml 
of fAd for 30min. Cells were fixed, visualized and quantified using ImageJ software plugin 
JACop to obtain Person Correlation Coefficient values of nuclear overlap for both FOXO1 and 
pFOXO1. 
 Primary antibodies FOXO1 (#9454S) and pFOXO1 (Thr24) (#9464L) were obtained from 
Cell signalling. Secondary anti-rabbit Alexa Fluor 488 conjugate anti-body (#A-11008) was 
obtained from ThermoFisher Scientific (via VWR).  
3.3.5 Glucose uptake  
 Glucose uptake was performed using GLUT4-myc L6 myoblasts. Cells were seeded 
onto a 24 well plate (Falcon #353047), and starved with 0.5% FBS DMEM. Cells were treated 
with 250µm of FeCl3 for 24h and 20µm of AdRon for 1h. As a positive control for glucose 
uptake, cells were treated with 100nm of insulin for 10 minutes. Glucose uptake protocol as 
previously described was followed from this point onward.  
3.3.6 In vivo Iron Overload Mouse Model 
 Six 8 week C57 male mice were intraperitoneally (IP) injected with 10mg/g of ferrous 
form iron dextran for 4 weeks, 5 days per week. Soleus tissue was collected, homogenized and 
immunoblotted as previously described. The prepared samples were blotted for the following 
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proteins: AdipoR1, AdipoR2, APPL2, APPL2, FOXO1 and β-actin. AdipoR1, and AdipoR2 
primary antibodies were kindly gifted from AstraZeneca (Sweden). APPL1 antibody was 
purchased from Antibody Immunoassay Services (AIS, Hong Kong). APPL2 antibody (#H00055 
198-B01P) was obtained from Abnova. GAPDH (#2118L) antibody was obtained from Cell 
Signalling.   
2.3.6.1. Prussian blue staining 
 Fresh soleus tissue was preserved in tissue freezing medium (Electron Miscroscopy 
Sciences #72592) and cut into 10µm slices via cryosectioning. Cryosections were sent to 
London Health Sciences Centre at University Hospital, London, ON, for Prussian blue staining. 
3.3.6.1. ITT 
 For insulin tolerance testing, mice were starved for 6h and IP injected with 1unit/kg of 
body weight after 3 weeks of iron injections. Plasma glucose levels were measured at 0, 20, 40, 
60 and 80 minutes using a glucose meter (Accu-check #0088). 
3.3.6.2. GTT 
 For glucose tolerance testing, mice were starved for 16h and IP injected with 2g/kg of 
body weight after 4 weeks of iron injections. Plasma glucose levels were measured at 0, 15, 30, 
60 and 120 minutes using a glucose meter. 
3.3.6.3. Urine glucose 
 To test for glucose content in the urine, mice were starved for 0h and 6h. Urine glucose 
levels were measured using a glucose meter. 
3.3.7. Statistical Analysis 
 Statistical analysis between two groups was done using an unpaired two-tailed t-test. P 
values less than 0.05 were accepted as significant.  
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3.4 Results 
3.4.1. Characterizing intracellular iron in L6 myoblasts  
 Intracellular iron overload was characterized in L6 myoblasts via IRE activity as 
previously described. Upon 24h hour treatment of iron, a significant 5.5 fold increase in CFP 
expression was observed in iron overload conditions compared to non-treated cells (Figure 3.1 
A-C). Overall, these results confirm iron overload via the activation of intracellular iron 
regulatory processes.  
 
 
 
Figure 3.1: Characterizing intracellular iron overload in vitro. Increased iron response 
element activity was observed under iron overload conditions. L6 myoblasts were transfected 
with IRE-CFP plasmid, and treated with 250µm of FeCl
3
 24h (n=3). Transcribed cyan 
fluorescent protein was observed via FITC channels by confocal microscopy. A) 2D 
representative image taken using ZEN software (Scale bar: 2µm). B) 3D representative images 
created using IMARIS software (Scale bar: 10µm). C) 3-5 fields of view were taken per 
condition. All cells in field of view were traced and quantified using ImageJ software. Mean 
intensity values per cell were averaged and plotted for analysis. Statistical analysis was 
compared to IRE-CFP. (* = P < 0.05). Error bars display standard error of the mean.  
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4.2. Iron overload induced adiponectin resistance in L6 myoblasts 
 After characterizing intracellular iron overload, the potential for iron overload induced 
adiponectin resistance was further investigated. After 24h iron overload treatment, western blot 
analysis was used to examine the expression and regulation of the following proteins: AdipoR1, 
APPL1, AdipoR2, APPL2, pAMPK and adiponectin.  A decrease in AdipoR1 and APPL1 
expression were observed in iron overload conditions (Figure 3.2 A and B), however, no 
changes in AdipoR2 and APPL2 expression were observed (Figure 3.2 C and D). Moreover, 
iron overload conditions also reduced adiponectin monomer expression (Figure 3.2 F). L6 
myoblasts were treated with fAd 30min prior to the end of iron treatment. Adiponectin sensitivity 
under iron overload conditions were analysed via pAMPK. With adiponectin only treatment, 
pAMPK levels increased compared to control. However, a decrease in pAMPK stimulation was 
evident in iron overload conditions when co-treated with adiponectin (Figure 3.2 E). Together, 
these results confirmed iron overload induced adiponectin resistance via reduced expression of 
adiponectin signalling markers, as well as through a reduction adiponectin sensitivity via 
pAMPK.   
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Figure 3.2: Iron overload induced adiponectin resistance via adiponectin signalling. L6 
myoblasts were treated with 250µM of FeCl
3
 FeSO
4
 for 24h, and with 5µg/ml of fAd for 30min 
(Part E only). Cells were lysed, and proteins of interest were analyzed by Western blotting. 
Proteins of interest were tagged with the following primary antibodies: AdipoR1, APPL1, 
AdipoR2, APPL2, pAMPK, adiponectin and GAPDH, which were subsequently tagged with 
HRP-conjugated secondary antibodies (n=4). (A-F) Representative western blots of AdipoR1, 
AdipoR2, APPL1, APPL2, pAMPK, adiponectin and GAPDH. Quantitative representation of 
AdipoR1, AdipoR2, APPL1, APPL2, pAMPK and adiponectin. Western blot band intensity was 
quantified using ImageJ software, normalized to β-actin, and further normalized to control. 
Statistical analysis was compared to control conditions (* = P < 0.05). Error bars display 
standard error of the mean.  
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3.4.3. Iron overload regulation by FOXO1 in L6 myoblasts 
 After the confirmation of iron overload induced adiponectin resistance in L6 myoblasts, 
the regulation of iron overload by FOXO1 was further investigated. L6 skeletal muscle cells 
were treated with iron overload conditions for 0.5, 1, 2, 4 and 24h. Immunofluorescence was 
used to investigate changes in cellular localization of total FOXO1 and pFOXO1 (Thr24) under 
iron overload conditions. Pearson's overlap correlation coefficient (PCC) was used to monitor 
total FOXO1 and pFOXO1 colocalization with the nucleus. An increase in PCC suggests an 
increase in nuclear overlap, while a decrease in PCC suggests cytoplasmic localization. A 
decreased PCC of total FOXO1 was observed at 1h compared to control, however recovers 
back to basal levels at 2h. At 4h, FOXO1 levels continue to decrease below 1h levels, following 
a significant decrease in PCC at 24h (Figure 3.3 A, B and E). In terms of pFOXO1, PCC 
gradually increased from 0h to 4h. However, a significant decrease in PCC of pFOXO1 was 
evident at 24h time point (Figure 3.3 C, D and F). To conclude, this data shows that total 
FOXO1 and pFOXO1 is involved in the regulation of iron overload in L6 myoblasts 
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Figure 3.3: Iron overload conditions induced total FOXO1 and pFOXO1 cytoplasmic 
localization.  
(A-B and E) Iron overload conditions induced total FOXO1 cytoplasmic localization. L6 
myoblasts were treated with 250µM of FeCl3 for 0, 0.5, 1, 2, 4 and 24h.  Cells were fixed and 
incubated in total FOXO1 primary antibody, and subsequently incubated in Alexa 488 
secondary antibody. Green fluorescence was observed via FITC channels by confocal 
microscopy (n=3). A) 2D representative images of FOXO1 taken using ZEN software (Scale bar: 
2µm). B) 3D representative images of FOXO1 created using IMARIS software (Scale bar: 
10µm). (E) 3-5 fields of view were taken per condition. All cells in field of view were quantified 
using ImageJ software. ImageJ plugin JACop was used to obtain Person Correlation Coefficient 
values of nuclear overlap of FOXO1. Mean correlation values were averaged, and normalized to 
control. Statistical analysis was compared to 0h (* = P < 0.05). Error bars display standard error 
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of the mean.  
(C-D and F) Iron overload conditions induced pFOXO1 (Thr24) cytoplasmic localization. 
L6 myoblasts were treated with 250µM of FeCl3 for 0, 0.5, 1, 2, 4 and 24h.  Cells were fixed and 
incubated in pFOXO1 primary antibody, and subsequently incubated in Alexa 488 secondary 
antibody. Green fluorescence was observed via FITC channels by confocal microscopy (n=3). 
A) 2D representative images of pFOXO1 taken using ZEN software (Scale bar: 2µm). B) 3D 
representative images of pFOXO1 created using IMARIS software (Scale bar: 10µm). (F) 3-5 
fields of view were taken per condition. All cells in field of view were quantified using ImageJ 
software. ImageJ plugin JACop was used to obtain Person Correlation Coefficient values of 
nuclear overlap of FOXO1. Mean correlation values were averaged, and normalized to control. 
Statistical analysis was compared to 0h (* = P < 0.05). Error bars display standard error of the 
mean.  
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3.4.4. Iron overload induced adiponectin resistance regulated by FOXO1 
 Following the confirmation of FOXO1's role in iron overload, iron overload induced 
adiponectin resistance regulation by FOXO1 was further investigated. Firstly, L6 myoblasts 
were treated with iron overload conditions, later stimulated with fAd 30min prior to end of iron 
overload treatments. Immunofluorescence featuring total FOXO1 and pFOXO1 (Thr24) was 
used to investigate changes in cellular localization iron overload induced stimulated with fAd. 
Insulin and AdRon treatments increased total FOXO1 and pFOXO1 nuclear colocalization via 
an increase in PCC. Co-treatment with iron overload and fAd conditions caused both total 
FOXO1 and pFOXO1 localization to the cytoplasm as indicated by a decreased in PCC (Figure 
3.4 A-F). Therefore, this suggests iron overload induced adiponectin resistance via changes in 
localization of total FOXO1 and pFOXO1. 
 In addition, iron overload induced adiponectin resistance regulation by FOXO was 
examined via glucose uptake. L6 myoblasts over-expressing GLUT4 receptors were treated 
with FOXO inhibitor, AS1842856, 30min prior to 24h iron overload conditions iron overload 
conditions for 24h, following 30min of AdRon treatment prior to end of iron overload treatments. 
A decrease in glucose uptake was observed in iron overload conditions with AdRon compared 
to AdRon only conditions. Moreover, treating L6 myoblasts with AS1842856, iron and AdRon 
alleviated glucose uptake levels back to AdRon only conditions (Figure 3.4 G). Furthermore, 
AS1842856 alone significantly increased glucose uptake as well. To conclude, this data also 
shows iron overload induced adiponectin resistance via AdRon stimulated glucose uptake, and 
further the regulation by FOXO via AS1842856. 
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Figure 3.4: Iron overload induced adiponectin resistance via fAd stimulated pFOXO1 and 
AdRon stimulated glucose uptake.  
(A-B and E) Iron overload causes reduced fAd induced cytoplasmic localization of total 
FOXO1 and pFOXO1. L6 myoblasts were treated with 250µM of FeCl3 for 24h, and 5µg/ml of 
fAd for 30min prior to the end of iron overload incubation. Insulin (100nm for 10min) and AdRon 
(20µM for 30min) was used as a positive control cytoplasmic localization of total FOXO1. Cells 
were fixed and incubated in total FOXO1 primary antibody, and subsequently incubated in Alexa 
488 secondary antibody. Green fluorescence was observed via FTIC channels by confocal 
microscopy (n=2). A) 2D representative images of FOXO1 taken using ZEN software (Scale bar: 
2µm). B) 3D representative images of FOXO1 created using IMARIS software (Scale bar: 
10µm). E) 3-5 fields of view were taken per condition. All cells in field of view were quantified 
using ImageJ software. ImageJ plugin JACop was used to obtain Person Correlation Coefficient 
values of nuclear overlap of FOXO1. Mean correlation values per cell were averaged, and 
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normalized to control. Statistical analysis was compared to basal (* = P < 0.05) or fAd (# = P < 
0.05). Error bars display standard error of the mean.  
(C-D and F) Iron overload causes reduced fAd induced cytoplasmic localization of 
pFOXO1 (Thr24). L6 myoblasts were treated with 250µM of FeCl3 for 24h, and 5µg/ml of fAd for 
30min prior to the end of iron overload incubation. Insulin (100nm for 10min) and AdRon (20µM 
for 30min) was used as a positive control cytoplasmic localization of pFOXO1 (Thr24). Cells 
were fixed and incubated in pFOXO1 (Thr24) primary antibody, and subsequently incubated in 
Alexa 488 secondary antibody. Green fluorescence was observed via FTIC channels by 
confocal microscopy (n=2). C) 2D representative images of pFOXO1 taken using ZEN software 
(Scale bar: 2µm). D) 3D representative images of pFOXO1 created using IMARIS software 
(Scale bar: 10µm). F) 3-5 fields of view were taken per condition. All cells in field of view were 
quantified using ImageJ software. ImageJ plugin JACop was used to obtain Person Correlation 
Coefficient values of nuclear overlap pFOXO1. Mean correlation values per cell were averaged, 
and normalized to control. Statistical analysis was compared to basal (* = P < 0.05) or fAd (# = 
P < 0.05). Error bars display standard error of the mean. 
(G) Iron overload induced adiponectin resistance via glucose uptake is regulation by 
FOXO1.  L6 GLUT4-myc myoblasts were treated with 250µm of FeCl3 for 24h, and 20µM of 
AdRon 30min prior to end of treatment time. 30min prior to iron incubation, cells were treated 
with 1µM of FOXO inhibitor, AS1842856. As a positive control, cells were stimulated with 100nM 
of insulin for 10 minutes. Cells were treated with radioactive H3 2 deoxy-D-(3H) – glucose for 
5min. Cells were lysed, collected for scintillation counting, and corrected for protein 
concentration. (n=4). Statistical analysis was compared to control (* = P <0.05) and compared 
to AdRon (# = P <0.05). Error bars display standard error of the mean.  
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3.4.5. Iron overload induced adiponectin resistance regulation by FOXO1 via adiponectin 
signalling 
 Iron overload induced adiponectin resistance regulation by FOXO was further 
investigated. L6 skeletal muscle cells were treated with a FOXO1 inhibitor AS1842856 for 30min 
prior to 24h iron overload conditions. Western blot analysis was used to investigate the 
expression of the following proteins: AdipoR1, APPL1 and AdipoR2.  AdipoR1 expression 
decreased by 50% under iron overload conditions. Moreover, AS1842856 increased AdipoR1 
expression, following a further increase in iron overload and AS1842856 conditions (Figure 3.5 
B). APPL1 and AdipoR2 expression did not change in iron overload conditions; however, an 
increase was also evident under AS1842856 conditions (Figure 2.5 C and D). (Note: no bands 
were present for APPL2 and require further optimization).  In terms of iron and AS1842856 
conditions, no obvious trend was observed in APPL1 and AdipoR2 expression compared to 
AS1842856 only conditions. To conclude, this data shows that iron overload induced 
adiponectin resistance regulation by FOXO via expression is unclear.  
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Figure 3.5: Iron overload induced adiponectin resistance regulation by FOXO via 
adiponectin signalling. L6 myoblasts were treated with 250µM of FeCl3 for 24h, and 1µM of 
AS1842856 30min prior to iron overload incubation. Cells were lysed, proteins of interest were 
analyzed by Western blotting. Proteins of interest were tagged with the following primary 
antibodies: AdipoR1, APPL1 and AdipoR2 and β-actin, which were subsequently tagged with 
HRP-conjugated secondary antibodies (n=1). A) Representative western blots of AdipoR1, 
APPL1, AdipoR2 and β-actin. B-D) Quantitative representation of AdipoR1, APPL1 and 
AdipoR2. Western blot band intensity was quantified using ImageJ software, normalized to β-
actin, and further normalized to control.  
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3.4.6. In vivo iron overload induced adiponectin resistance in skeletal muscle 
 Iron overload induced adiponectin resistance was further examined in the skeletal 
muscle of previously described iron overload mice. Male C57 mice of 8 weeks were IP injected 
with 10mg/g of ferrous iron for 4 weeks. Prussian blue staining of soleus tissue cryosections 
was conducted. An increase in Prussian blue staining was observed in iron overload mice 
compared to control mice, confirming irons ability to reach the target tissues (Figure 3.7 A-B). 
Western blot analysis of AdipoR1, APPL1, AdipoR2, and APPL2 was used to examine changes 
in gene expression of adiponectin signalling molecules (Figure 3.7 A-D). Results indicate no 
changes were evident in AdipoR1 and AdipoR2 expression. However, a significant increase by 
approximately two fold was seen in APPL1. Similar to the heart, a significant loss in APPL2 
expression by approximately 90% was seen in iron overload mice compared to control. In 
conclusion, this model shows the presence of iron overload induced adiponectin resistance via 
a significant reduction in APPL2 expression.  
 
3.4.6.1. Glucose metabolism 4 week iron overload mice 
 Next, glucose metabolism was investigated to characterize metabolic profiles in iron 
overload mice. Iron overload mice were starved for 6h and injected with insulin at various time 
points in order to investigate insulin tolerance via analysis of plasma glucose levels. In control 
mice, plasma glucose levels dropped by 50% during 0 to 20 minute time points, followed by 
steady plasma glucose levels up to 80min. However, plasma glucose levels iron overload mice 
gradually decreased by 50% at 0 to 40min, followed by a steady level of glucose up to 80min 
(Figure 3.8 A). Moreover, iron overload had significantly less plasma glucose levels compared 
to control mice as indicated by area under curve (AUC) (Figure 3.8 B). Next, iron overload mice 
were starved for 16h and injected with glucose at various time points for glucose tolerance 
testing. Control mice displayed a spike in glucose levels at 15min time-point by a 4 fold, 
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followed by a rapid decrease in plasma glucose levels at 1h. Iron overload mice doubled their 
plasma glucose levels at 15min, followed by a steady decline in glucose levels at 1h. Moreover, 
both control and overload mice plasma glucose levels plateau from 1h to 2h time points (Figure 
3.8 C). Furthermore, iron overload mice show overall lower plasma glucose levels compared to 
control mice (Figure 3.8 D). Lastly, urine glucose levels were compared in control and iron 
overload mice after either 0h or 6h of starvation. At 0h, control mice show no level of urine 
glucose levels, however, iron overload mice have approximately 1.5mmol/L of glucose levels in 
urine (Figure 3.8 E). Conversely, iron overload mice show a decrease by 50% in urine glucose 
levels at 6h of starvation compared to control mice. These data suggests an altered metabolic 
profile in iron overload load via changes in plasma and urine glucose levels.  
 
 
Figure 3.6: Characterizing iron overload in vivo. Iron overload mice display increased 
amount of Prussian blue staining compared to control. 8 week C57 male mice were IP injected 
with 10mg/g of ferrous iron. Soleous tissue cryosections were stained with Prussian blue and 
analyzed by histopathology. (n=3). A) Representative image of control mice. B) Representative 
image of iron overload mice. Original magnification X100 for all micrographs. 
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Figure 3.7: Iron overload altered adiponectin signalling in vivo via changes in expression 
of adiponectin signalling proteins.  8 week C57 male mice were IP injected with 10mg/g of 
ferrous iron. Soleus tissue was lysed, and proteins of interest were analyzed by Western 
blotting. Proteins of interest were tagged with the following primary antibodies: AdipoR1, 
APPL1, AdipoR2, APPL2 and β-actin, which were subsequently tagged with HRP-conjugated 
secondary antibodies (n=6). A) Representative western blots of AdipoR1, APPL1, AdipoR2, 
APPL2 and β-actin. B-E) Quantitative representation of AdipoR1, APPL1, AdipoR2 and APPL2. 
Western blot band intensity was quantified using ImageJ software, normalized to β-actin, and 
further normalized to control. Statistical analysis was compared to control conditions (* = P < 
0.05). Error bars display standard error of the mean. Note: For uncut Western blots, see 
Appendix A: Figure A3. 
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Figure 3.8: Iron overloads effect on glucose blood and urine levels in an in vivo iron 
overload mouse model. 8 week C57 male mice were IP injected with 10mg/g of ferrous iron. 
A) Insulin tolerance test (ITT). Mice were starved for 6h and injected with 1unit/kg of body 
weight after 3 weeks of iron injections. Plasma glucose levels were measured at 0, 20, 40, 60 
and 80 minutes using a glucose meter. B) Displays area under the curve of ITT. C) Glucose 
tolerance test (GTT). Mice were starved for 16h and IP injected with 2g/kg of body weight after 4 
weeks of iron injections. Plasma glucose levels were measured at 0, 15, 30, 60 and 120 
minutes using a glucose meter. D) Displays area under the curve of GTT. (E-F) Urine glucose 
test. Mice were starved for 0h and 6h, respectively. Urine glucose levels were measured using a 
glucose meter. Statistical analysis was compared to control conditions (* = P < 0.05). Error bars 
display standard error of the mean.  
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3.5 Discussion 
3.5.1 Iron overload activated IREs in L6 myoblasts 
 An IRE-CFP reporter assay was used to confirm IRE activation upon iron overload 
treatment in L6 myoblasts. As mentioned previously, this construct contains a sequence that 
encodes the ferritin promoter region upstream of CFP112. As with NeoCM, 24h iron overload 
conditions increased CFP levels cyan suggesting an increase in ferritin expression (Figure 3.1 
A-C). This confirms iron-stimulated gene expression of iron regulatory proteins upon iron 
overload treatment. Moreover, our lab has also showed time-dependant PGSK quenching, and 
confirmed no changes in cell viability using MTT in L6 myoblasts (Jang et al, unpublished data).  
 
3.5.2. Iron overload induced adiponectin resistance in L6 myoblasts: changes in adiponectin 
signalling and adiponectin expression 
 The potential for adiponectin resistance in L6 myoblasts was suggested by a significant 
decrease in AdipoR1 after iron overload, which has also been suggested recently in the 
literature79.  Additionally, APPL1 levels were decreased under iron overload conditions; however 
no significant changes in AdipoR2 and APPL2 were evident (Figure 3.2 A-F). These results are 
also consistent with NeoCM adiponectin signalling (Figure 2.5 A-E). In terms of adiponectin 
sensitivity, a decrease pAMPK was evident in iron overload conditions when co-treated with 
adiponectin, suggesting adiponectin resistance can also occur downstream of adiponectin 
receptor level expression84. This finding is also consistent to NeoCM anti-pAMPK 
immunofluorescence (Figure 2.2 A-C). Iron overload conditions also decreased adiponectin 
monomer expression, a phenomenon that has also been characterized previously in 
adipocytes106. Overall, this data confirms iron overload induced adiponectin resistance in L6 
myoblasts.  
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3.5.3. Iron overload induced adiponectin resistance is regulated by FOXO1 in L6 myoblasts 
 As previously discussed in NeoCM, FOXO1 - a transcription factor regulator of AdipoR1 
and AdipoR2 expression - has been recently suggested as a mechanistic mediator of iron 
overload induced adiponectin resistance106. By inhibiting FOXO1 DNA binding with AS1842856, 
I have demonstrated that FOXO1 plays a role in iron overload induced adiponectin resistance 
regulation; this has been demonstrated by changes in AdipoR1 and pAMPK. In NeoCM, the 
decrease of expression with iron overload is recovered after inhibition of FOXO1, suggesting 
that when FOXO1 is inhibited, adiponectin resistance is no longer under its mechanistic 
regulation (Figure 2.4 A-C). 
 A different approach was used in L6 myoblasts by observing cellular localization of 
FOXO1. Changes in FOXO1 localization were observed in a time dependant matter via an iron 
overload time course in L6 myoblasts. At 24h of iron overload conditions, PCC values of total 
FOXO1 and pFOXO1 (Thr24) levels decrease significantly compared to control. This suggests 
that iron overload regulates FOXO1 translocation to the cytoplasm. Moreover, upon cytoplasmic 
translocation, FOXO1 can no longer act in the nucleus to regulate AdipoR1 and AdipoR2 
transcription, suggesting that this may be a potential mechanism to cause a decrease in 
AdipoR1 expression (Figure 3.3 A-C).  
 This was further investigated by observing FOXO1 expression and regulation via iron 
overload conditions stimulated with adiponectin. Previously, it was already established that an 
increase in FOXO1 localization was observed in iron overload conditions. In adiponectin only 
conditions, adiponectin caused no significant change in FOXO1 expression or localization 
compared to control conditions (Figure 3.4 A-C). However, during iron overload conditions with 
adiponectin, a decrease in nuclear overlap was observed in comparison to adiponectin only 
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conditions, further supporting that FOXO1 regulates iron overload induced adiponectin 
resistance in skeletal muscle. 
3.5.4 Iron overload induced adiponectin resistance: analysis of AdRon stimulated glucose 
uptake in GLUT4-myc L6 myoblasts 
 Glucose uptake is a read-out of adiponectin action, as adiponectin has been shown to 
stimulate GLUT4 mediated glucose uptake in previous literature21. A decrease in glucose 
uptake was observed in iron overload and AdRon conditions compared to AdRon only 
conditions (Figure 3.3 G). This further supports that iron overload conditions suppresses AdRon 
which normally stimulate glucose uptake77. Moreover, this is also supported by consistent 
findings in glucose uptake using NeoCM (Figure 2.2 G). 
 FOXO1 inhibitor was used in combination with iron overload and AdRon treatments in L6 
myoblasts in order to investigate the mechanistic regulation of iron overload induced 
adiponectin resistance (Figure 3.3 G). In terms of adiponectin regulation, FOXO1 inhibitor 
recovers iron overload and AdRon glucose uptake levels, back to AdRon stimulated levels, 
supporting FOXO1's role in glucose metabolism regulation by AdRon. FOXO1 inhibitor 
AS1842856 significantly increased glucose uptake as well, which could be explained by 
FOXO1's role in glucose homeostasis in hemochromatosis 106. To conclude, this data suggests 
that FOXO1 plays a role in iron overload induced adiponectin resistance by mediating 
adiponectin sensitivity. 
3.5.6. FOXO1 mediated iron overload induced adiponectin resistance via adiponectin signalling 
 After establishing iron overload induced adiponectin resistance in L6 myoblasts via 
adiponectin signalling (Figure 2.3 A-F), potential regulation by FOXO was further investigated. 
FOXO1 inhibitor AS1842856 increased AdipoR1 expression, followed by a further increase in 
iron overload combined with AS1842856 (Figure 3.5 B). Similarly, an increase in APPL1 and 
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AdipoR2 was also evident using AS1842856 (Figure 2.5 C and D). In terms of iron and 
AS1842856 conditions, no obvious trend was observed in APPL1 and AdipoR2 expression 
compared to AS1842856 only conditions. In conclusion, FOXO1 may play a regulatory role in 
iron overload induced adiponectin resistance in L6 myoblasts via regulation of AdipoR1 
expression. This can be supported by previous literature, as FOXO1 is known to directly 
modulate AdipoR1 expression in skeletal muscle68,79. Conversely, iron overload induced 
adiponectin resistance regulation by FOXO via expression is unclear, and more replicates are 
required to confirm FOXO1 regulation in iron overload induced adiponectin resistance 
regulation. Furthermore, as previously investigated in NeoCM, FOXO1 may not play a 
regulatory role in iron overload induced adiponectin resistance regulation on the level of 
adiponectin signalling protein expression. Other potential mechanisms may be involved in the 
regulation of iron overload induced adiponectin resistance in skeletal muscle. 
3.5.6 Iron overload altered adiponectin signalling in skeletal muscle of in vivo iron overload 
mouse model  
 After examining iron overload induced adiponectin resistance in L6 skeletal muscle, 
further investigation in skeletal muscle of in vivo iron overload mice was investigated. Similar to 
investigations in the heart, Prussian blue staining was used to characterize iron overload in 
soleus muscle, whereby an increase in Prussian blue was observed in iron overload mice 
(Figure 3.6 A-B). Western blot analysis was used to investigate adiponectin signalling 
regulation in iron overload mice (Figure 3.7 A-E). Consistent with heart Western blot analysis, 
no change was observed in AdipoR1, APPL2 and although AdipoR2 levels show a decreasing 
trend, the reduction in expression is not significant. Additionally, a loss of APPL2 was observed 
in soleus muscle, like with heart Western blot analysis. Again, this indicates an increase in 
adiponectin signalling, rather than a resistance, due to the competitive inhibition of APPL1 by 
APPL2. This suggests a potential up-regulation in adiponectin receptor action via increased 
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APPL1 activation58. As previously discussed, these conflicting results call for further 
investigation to comprehend the severity of iron overload as a spectrum, and additionally, its 
effects on skeletal muscle metabolic regulation.  
3.5.6.1. Glucose metabolism is altered in iron overload mouse model 
 The investigation of glucose metabolism was crucial to understand an iron overload 
mouse model, due to the association of iron overload with diabetes102. Specifically, glucose 
metabolism of iron overload mice was investigated to characterize any changes in their 
metabolic profiles. This is because iron is known to be associated with glucose metabolism and 
insulin resistance regulation 103,104. First, an insulin tolerance test showed that iron overload 
mice display insulin resistance, a connection that has been recently well established135. This is 
shown by more stable glucose levels upon insulin injections in iron over load mice (Figure 3.8 
A). Moreover, iron overload mice display lower total plasma glucose levels compared to control 
(Figure 3.8 B). A study in hepcidin KO mice also observed reduced blood glucose levels in iron 
overload mice. These findings confirm iron overloads ability to impair glucose homeostasis in 
mice136, which can be explained by increased iron deposition in the liver136; an observation also 
made in the liver of our iron overload mice (data not shown) (Dang et al, unpublished data). In 
terms of glucose tolerance, these iron overload mice seem to display a higher glucose tolerance 
(Figure 3.8 C). Conversely, previous literature has also indicated an up-regulation of glucose 
with iron overload135, though the glucose tolerance observed is not significant as indicated by 
AUC (Figure 3.8 D). To conclude, abnormal glucose tolerance and diabetes are also evident in 
patients with hereditary iron overload and require further elucidation137. Lastly, to further 
examine the discrepancies in glucose metabolism in iron overload mice, urine glucose was 
measured in starved (6h) and non-starved mice. At 0h starvation, iron overload mice showed 
elevated urine glucose levels, compared to control mice which show no levels of urine glucose 
(Figure 3.8 E). Moreover, no significant changes were observed in urine glucose levels at 6h 
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starvation in iron overload mice compared to control. These findings are similar to clinical trials 
of hemochromatosis patients, whereby an increase in urine glucose, medically known as 
glycosuria, is also observed in these patients138. Overall, these results indicate iron overload's 
ability to cause altered glucose metabolism via the presence of insulin resistance and 
glycosuria, both of which are known characteristics of diabetes. 
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Chapter 4: General conclusions and future directions 
 
 Metabolic syndrome is characterized by a combination of reversible, physiological  
abnormalities that are associated with severe health conditions such as cardiovascular disease 
and diabetes1. Although cardiovascular disease is known to be the number one cause of death 
worldwide5, and the incidence of heart failure is steadily increasing 139. While a link has been 
previously made with heart disease and metabolic syndrome4, the molecular regulation of 
cardiovascular disease requires further investigation. Diabetes is also positively correlated to 
metabolic syndrome12,13. Diabetes prevalence is also increasing, resulting in a diabetes 
epidemic in some countries140. While recent research has developed further conclusions 
towards molecular and physiological cardiovascular disease and diabetes regulation, further 
investigation is needed to better understand metabolic profiling in disease.  
Iron overload has shown to be associated with heart failure and diabetes regulation. Iron 
overload is a clinical condition that can result from the accumulation of intracellular or circulatory 
iron, which can cause organ dysfunction and damage97,98. The correlative relationship between 
iron overload and heart disease is illustrated by iron overload having recently been linked 
cardiac oxidative stress and fibrosis100. However, the clinical implications of iron overload 
induced cardiovascular disease still requires further characterization. Moreover, the link 
between diabetes and iron overload has recently been well established, mainly due to irons role 
in glucose homeostasis 103,104. At the molecular level, iron overload is not well characterized in 
cardiovascular disease and diabetes regulation, and further, the regulation of iron overload via 
adipokine signalling - such as adiponectin - also currently remains misunderstood and requires 
further investigation.  
By examining the regulation of iron overload induced adiponectin resistance in the heart 
and skeletal muscle, I have shown that adiponectin regulation is similarly altered by iron 
overload conditions in both tissues. First, I showed that iron accumulation occurs in both 
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NeoCM and L6 myoblasts after iron overload treatment, using PGSK and IRE-CFP assays. 
Next I have proved iron overload adiponectin resistance occurs in both models. This was 
characterized by a decrease in AdipoR1 and APPL1 protein expression under iron overload 
conditions in both NeoCM and L6 cells. Moreover, I confirmed lack of adiponectin signalling via 
AdRon induced pAMPK and pP38 in NeoCM, and fAd stimulated pAMPK in L6 myoblasts. I 
have showed AdRon induced that glucose uptake is impaired by iron overload in NeoCM and 
GLUT4-myc L6 myoblasts.  
Next, I have confirmed the mechanistic regulation of iron overload induced adiponectin 
resistance via FOXO1 in both models. In NeoCM and L6 myoblasts, I found that total FOXO1 
and pFOXO1 cellular localization changed to the cytoplasm under iron overload conditions. In 
NeoCM, I showed an alleviation of AdRon stimulated pAMPK signalling under iron overload 
conditions using a FOXO1 inhibitor. While in L6, I used a different approach by showing a 
change pFOXO1 localization to the cytoplasm when treated with iron overload and fAd. 
However, when examining protein expression of AdipoR1/2 and APPL1/2 with FOXO1 inhibitor, 
both models indicated no significant change in protein expression, suggesting FOXO1 
regulation of iron overload adiponectin resistance only occurs on the level of adiponectin 
sensitivity. 
 Moreover, I investigated adiponectin signalling in an iron overload mouse model, 
focusing on heart and soleus muscle. I started by confirming iron overload deposition to the 
tissues via Prussian blue staining. I then used western blot analysis to examine changes in the 
following adiponectin signalling proteins: AdipoR1/2 and APPL1/2. Although adiponectin 
resistance was not observed in both tissues by a marked reduction in AdipoR1 and APPL1 
expression, both heart and soleus muscle showed a complete loss of APPL2, suggesting a 
potential up-regulation in adiponectin signalling. Moreover, I confirmed that iron overload mice 
display altered cardiac functioning, glucose metabolism, and reduced body mass, which in turn 
correlate with iron overload induced disease studies.  
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In future, it is important to characterize a mechanism for the reduction of AdipoR1 and 
APPL1 in both NeoCM and L6 myoblasts. For instance, JNK and CDK1 have been shown to 
modulate FOXO1 activity via acetylation, and therefore may have the potential to regulate iron 
overload induced adiponectin resistance on the level of FOXO1 regulation65. More so, SIRT1/2 
and CBP/p300 regulate FOXO by either promoting or deactivating transcription, 
respectively70,69, and thus may also have the potential to indirectly regulate iron overload 
induced adiponectin resistance. Furthermore, over-expressing FOXO1 under iron overload 
conditions could help elucidate it`s role adiponectin receptor level regulation. Previous literature 
in adipocytes showed increased AdipoR1/2 expression under constituently active FOXO1; 
however, AdipoR1/2 levels were reduced despite FOXO1 up-regulation, due to inactive FOXO1 
regulation under stress conditions68. In addition, it is important to further characterize 
adiponectin resistance in L6 myoblasts via pAMPK regulation. Anti-pAMPK 
immunofluorescence featuring AdRon, iron overload and AS1842856 will confirm iron overload 
induced adiponectin resistance and FOXO1 regulation via the investigation of adiponectin 
sensitivity.  
Lastly, characterizing iron overload induced adiponectin resistance in an in vivo model is 
necessary to understand the physiological mechanisms of iron overload induced cardiovascular 
disease and diabetes. This can be accomplished via the optimization of iron overload as a 
spectrum by either decreasing or increasing iron overload injections to achieve an adiponectin 
resistant state. Genetic iron overload models, or orally induced iron overload may also be of 
interest to help to achieve this effect. Once this is confirmed, an iron overload model stimulated 
with either fAd or AdRon can be used to investigate adiponectin sensitivity via pAMPK and pP38 
levels. Furthermore, a cardiac or muscle specific FOXO1 KO mouse model can help elucidate a 
mechanistic perspective towards iron overload induced adiponectin resistance after the 
confirmation of reduced pAMPK and pP38 levels under iron overload alone.  
In summary, adiponectin resistance is beginning to be characterized in fields of 
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molecular biology and physiology in recent research. My studies show that iron overload 
induced adiponectin resistance occurs in heart and skeletal muscle models via changes in 
adiponectin signalling. Moreover, I have confirmed the regulation of iron overload induced 
adiponectin resistance by the FOXO1 transcription factor. Despite these conclusions, further 
investigation is required to fully elucidate adiponectin regulation in diseased states in order to 
better understand the balance between adiponectin resistance and adiponectin signalling up-
regulation. To conclude, iron overload induced adiponectin resistance and its underlying 
mechanisms is a phenomenon that should be continue to be elucidated in order to determine 
precise mechanistic understanding that will be useful to metabolic syndrome related disease 
drug targeting.  
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Appendix A: Supplementary Figures 
 
Figure A1: Optimizing AdRon treatment concentration and time via stimulation of 
pAMPK. NeoCM were treated with 0, 10, 20 and 40µM of AdRon for 0, 15, 30 and 60 min. 
20µM for 30min was used as treatment conditions for future studies. Cells were incubated in 
pAMPK (Thr172) primary antibody, and subsequently incubated in Alexa 488 secondary 
antibody. Green fluorescence was observed via FTIC channels by confocal microscopy (n=1). 
A) 2D representative image taken using ZEN software (Scale bar: 1µm). B) 3-5 fields of view 
were taken per condition. All cells in field of view were traced and quantified using ImageJ 
software. Mean intensity values per cell were averaged, and normalized to control. Error bars 
display standard error of the mean.  
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Figure A2: Optimizing AdRon and fAd treatment time via cytoplasmic localization of 
pFOXO1 . L6 myoblasts were treated with 20µM of AdRon, or 5µg/ml of fAd, for 15, 30 or 
60min. As a positive control for cytoplasmic pFOXO1 localization, cells were stimulated with 
100nM of insulin for 10 minutes (n=1). 30min time point was used for future experiments due to 
increase in cytoplasmic green fluorescence. Cells were incubated in pFOXO1 (Thr24) primary 
antibody, and subsequently incubated in Alexa 488 secondary antibody.  Green fluorescence 
was observed via FTIC channels by confocal microscopy. 2D representative image taken using 
ZEN software.  
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Figure A3: Uncut Western Blots of Figures 2.7 and 3.6, respectively. Twelve 8 week C57 
male mice were IP injected with 10mg/g of ferrous iron. 3 control and 3 iron overload mice were 
injected with 25mg/kg of AdRon for 30 min prior to sacrifice; however, AdRon injected mice 
were not considered for this study and require further optimization. Heart and soleus tissue were 
immunoblotted with primary antibody for the following proteins of interest: AdipoR1, APPL1, 
AdipoR2, APPL2, total FOXO1 and β-actin, which were subsequently tagged with HRP-
conjugated secondary antibodies (n=3). A) Representative western blots of AdipoR1, APPL1, 
AdipoR2, APPL2, FOXO1 and β-actin in the heart. B) Representative western blots of AdipoR1, 
APPL1, AdipoR2, APPL2 and β-actin in soleus muscle. 
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